Document:

exv4w3

 

EXHIBIT 4.3

EXECUTION VERSION    

$165,000,000

Pier 1 Imports, Inc.

6.375% Convertible Senior Notes Due 2036

Registration Rights Agreement

February 14, 2006          

J.P. Morgan Securities Inc.

277 Park Avenue

9th Floor

New York, New York 10172

Ladies and Gentlemen:

     This Registration Rights Agreement (the “Agreement”) is made and entered into as of February
14, 2006, by and among Pier 1 Imports, Inc., a Delaware corporation (the “Company”), the Guarantors
(as defined below) and J.P. Morgan Securities Inc. (the “Initial Purchaser”) to that certain
Purchase Agreement, dated as of February 8, 2006 (the “Purchase Agreement”) among the Company, the
Guarantors and the Initial Purchaser.

     As an inducement to the Initial Purchaser to enter into the Purchase Agreement and in
satisfaction of a condition to the obligations of the Initial Purchaser thereunder, the Company
agrees with the Initial Purchaser, for the benefit of the holders (including the Initial Purchaser)
of the Notes and the Shares (as defined below) (collectively, the “Holders”), as follows:

     1. Certain Definitions.

     For purposes of this Registration Rights Agreement, the following terms shall have the
following meanings:

     (a) “Additional Interest” has the meaning assigned thereto in Section 2(d).

     (b) “Additional Interest Payment Date” has the meaning assigned thereto in Section
2(d).

     (c) “Agreement” means this Registration Rights Agreement, as the same may be amended
from time to time pursuant to the terms hereof.

     (d) “Closing Date” means the date on which any Notes are initially issued.

 

 

     (e) “Commission” means the Securities and Exchange Commission, or any other federal
agency at the time administering the Exchange Act or the Securities Act, whichever is the
relevant statute for the particular purpose.

     (f) “Company” has the meaning specified in the first paragraph of this Agreement.

     (g) “Deferral Notice” has the meaning assigned thereto in Section 3(b).

     (h) “Deferral Period” has the meaning assigned thereto in Section 3(b).

     (i) “Effective Period” has the meaning assigned thereto in Section 2(a).

     (j) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules
and regulations promulgated thereunder.

     (k) “Guarantors” means all of the domestic subsidiaries of the Company that are
signatories hereto and all of the direct and indirect future domestic subsidiaries of the
Company who execute a supplemental indenture in order to become Guarantors in accordance
with the terms of the Indenture.

     (l) “Guarantees” means the full and unconditional unsecured senior guarantees by the
Guarantors of the Notes in accordance with the terms of the Indenture.

     (m) “Holder” means each holder, from time to time, of Registrable Securities (including
the Initial Purchaser).

     (n) “Indenture” means the Indenture dated as of February 14, 2006 among the Company,
the Guarantors and JPMorgan Chase Bank, National Association, as Trustee, pursuant to which
the Notes are being issued.

     (o) “Initial Purchaser” has the meaning specified in the first paragraph of this
Agreement.

     (p) “Material Event” has the meaning assigned thereto in Section 3(a)(iv).

     (q) “Majority Holders” shall mean, on any date, holders of the majority of the Shares
constituting Registrable Securities; for the purposes of this definition, Holders of Notes
constituting Registrable Securities shall be deemed to be the Holders of the number of
Shares into which such Notes are or would be convertible as of such date.

     (r) “NASD” shall mean the National Association of Securities Dealers, Inc.

     (s) “NASD Rules” shall mean the Conduct Rules and the By-Laws of the NASD.

2

 

     (t) “Notes” mean the 6.375% Convertible Senior Notes Due 2036, to be issued under the
Indenture and sold by the Company to the Initial Purchaser.

     (u) “Notice and Questionnaire” means a written notice delivered to the Company
containing substantially the information called for by the Form of Selling Securityholder
Notice and Questionnaire attached as Annex A to the Offering Memorandum.

     (v) “Notice Holder” means, on any date, any Holder that has delivered a Notice and
Questionnaire to the Company on or prior to such date.

     (w) “Offering Memorandum” means the Offering Memorandum dated February 8, 2006 relating
to the offer and sale of the Securities.

     (x) “Person” means a corporation, association, partnership, organization, business,
individual, government or political subdivision thereof or governmental agency.

     (y) “Prospectus” means the prospectus included in any Shelf Registration Statement, as
amended or supplemented by any amendment or prospectus supplement, including post-effective
amendments, and all materials incorporated by reference or explicitly deemed to be
incorporated by reference in such Prospectus.

     (z) “Purchase Agreement” has the meaning specified in the first paragraph of this
Agreement.

     (aa) “Registrable Securities” means

	 	(a)	 	the Notes, including the Guarantees, until
the earliest of (i) their effective registration under the Securities
Act and the resale of all such Notes in accordance with the Shelf
Registration Statement, (ii) the expiration of the holding period
applicable to such Notes under Rule 144(k) or any successor provision
or similar provisions then in effect or (iii) the date on which all
such notes have been converted or otherwise cease to be outstanding;
	 
	 	(b)	 	the Shares, if any, issuable upon conversion
of the Notes, until the earliest of (i) their effective registration
under the Securities Act and the resale of all such Shares in
accordance with the Shelf Registration Statement, (ii) the expiration
of the holding period applicable to such Shares under Rule 144(k),
(iii) the date on which all such Shares are freely transferable by
persons who are not Affiliates of the Company without registration
under the Securities Act, or (iv) the date on which all such shares of
common stock cease to be outstanding.

3

 

     (bb) “Registration Default” has the meaning assigned thereto in Section 2(d).

     (cc) “Registration Expenses” has the meaning assigned thereto in Section 5.

     (dd) “Rule 144,” “Rule 405” and “Rule 415” mean, in each case, such rule as promulgated
under the Securities Act.

     (ee) “Securities” means, collectively, the Notes, the Guarantees and the Shares.

     (ff) “Securities Act” means the Securities Act of 1933, as amended, and the rules and
regulations promulgated thereunder.

     (gg) “Shares” means the shares of common stock of the Company, par value $1.00 per
share, into which the Notes are convertible or that have been issued upon any conversion
from Notes into common stock of the Company.

     (hh) “Shelf Registration Statement” means the shelf registration statement referred to
in Section 2(a), as amended or supplemented by any amendment or supplement, including
post-effective amendments, and all materials incorporated by reference or explicitly deemed
to be incorporated by reference in such Shelf Registration Statement.

     (ii) “Special Counsel” shall have the meaning assigned thereto in Section 5.

     (jj) “Trust Indenture Act” means the Trust Indenture Act of 1939, as amended, or any
successor thereto, and the rules, regulations and forms promulgated thereunder, all as the
same shall be amended from time to time.

     (kk) “Trustee” shall have the meaning assigned such term in the Indenture.

     Unless the context otherwise requires, any reference herein to a “Section” or “clause” refers
to a Section or clause, as the case may be, of this Agreement, and the words “herein,” “hereof” and
“hereunder” and other words of similar import refer to this Agreement as a whole and not to any
particular Section or other subdivision. Unless the context otherwise requires, any reference to a
statute, rule or regulation refers to the same (including any successor statute, rule or regulation
thereto) as it may be amended from time to time.

     2. Registration Under the Securities Act.

     (a) The Company and the Guarantors agree to file under the Securities Act as promptly
as practicable but in any event within 120 days after the Closing Date a shelf registration
statement providing for the registration of, and the sale on a continuous or delayed basis
by the Holders of, all of the Registrable Securities, and, if necessary by the Company of
all of the Shares, pursuant to Rule 415 or any similar rule that may be adopted by the
Commission. The Company and the Guarantors agree to use their reasonable best efforts to
cause the Shelf Registration Statement to become or be declared effective within 210 days
after the Closing Date and to keep such Shelf

4

 

Registration Statement continuously effective
until each of the Registrable Securities covered by the Shelf Registration Statement ceases
to be a Registrable Security (the “Effective Period”). None of the Company’s or any
Guarantor’s securityholders (other than Holders of Registrable Securities) shall have the
right to include any of the Company’s securities in the Shelf Registration Statement.

     (b) The Company and each Guarantor further agrees that they shall cause the Shelf
Registration Statement and the related Prospectus and any amendment or supplement thereto,
as of the effective date of the Shelf Registration Statement or such amendment or
supplement, (i) to comply in all material respects with the applicable requirements of the
Securities Act; and (ii) not to contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to make the
statements therein (in the case of the Prospectus, in the light of the circumstances under
which they were made) not misleading, and the Company and each Guarantor agrees to furnish
to the Holders of the Registrable Securities copies of any supplement or amendment prior to
its being used or promptly following its filing with the Commission; provided, however, that
the Company and each Guarantor shall have no obligation to deliver to Holders of Registrable
Securities copies of any amendment consisting exclusively of an Exchange Act report or other
Exchange Act filing otherwise publicly available on the Company’s website. If the Shelf
Registration Statement, as amended or supplemented from time to time, ceases to be effective
for any reason at any time during the Effective Period (other than because all Registrable
Securities registered thereunder shall have been sold pursuant thereto or shall have
otherwise ceased to be Registrable Securities), the Company and each Guarantor shall use
their reasonable best efforts to obtain the prompt withdrawal of any order suspending the
effectiveness thereof.

     (c) Each Holder of Registrable Securities agrees that if such Holder wishes to sell
Registrable Securities pursuant to the Shelf Registration Statement and related Prospectus,
it will do so only in accordance with this Section 2(c) and Section 3(b). From and after
the date the Shelf Registration Statement is declared effective, the Company and each
Guarantor shall, as promptly as is practicable after the date a Notice and Questionnaire is
delivered, and in any event within five (5) Business Days after such date,

     (i) if required by applicable law, file with the Commission a post-effective
amendment to the Shelf Registration Statement or prepare and, if required by
applicable law, file a supplement to the related Prospectus or a supplement or
amendment to any document incorporated therein by reference or file any other
required document so that the Holder delivering such Notice and Questionnaire is
named as a selling security holder in the Shelf Registration Statement and the
related Prospectus in such a manner as to permit such Holder to deliver such
Prospectus to purchasers of the Registrable Securities in accordance with applicable
law and, if the Company and each Guarantor shall file a post-effective amendment to
the Shelf Registration Statement, use their reasonable best efforts to cause such
post-effective amendment to be declared effective under the Securities Act as
promptly as is practicable;

5

 

     (ii) provide such Holder copies of any documents filed pursuant to Section
2(c)(i); and

     (iii) notify such Holder as promptly as practicable after the effectiveness
under the Securities Act of any post-effective amendment filed pursuant to Section
2(c)(i);

provided, that if such Notice and Questionnaire is delivered during a Deferral Period, the
Company shall so inform the Holder delivering such Notice and Questionnaire and shall take
the actions set forth in clauses (i), (ii) and (iii) above upon expiration of the Deferral
Period in accordance with Section 3(b). Notwithstanding anything contained herein to the
contrary, the Company shall be under no obligation to name any Holder that is not a Notice
Holder as a selling securityholder in any Shelf Registration Statement or related
Prospectus; provided, however, that any Holder that becomes a Notice Holder pursuant to the
provisions of this Section 2(c) (whether or not such Holder was a Notice Holder at the time
the Shelf Registration Statement was declared effective) shall be named as a selling
securityholder in the Shelf Registration Statement or related Prospectus in accordance with
the requirements of this Section 2(c).

     (d) If any of the following events (any such event a “Registration Default”) shall
occur, then additional interest (the “Additional Interest”) shall become payable by the
Company and each Guarantor to Holders in respect of the Notes as follows:

     (i) if the Shelf Registration Statement is not filed with the Commission within
120 days following the Closing Date, then commencing on the 121st day after the
Closing Date, Additional Interest shall accrue on the principal amount of the
outstanding Notes at a rate of 0.25% per annum for the first 90 days following such
121st day and at a rate of 0.5% per annum thereafter; or

     (ii) if the Shelf Registration Statement is not declared effective by the
Commission within 210 days following the Closing Date, then commencing on the
211th day after the Closing Date, Additional Interest shall accrue on the
principal amount of the outstanding Notes at a rate of 0.25% per annum for the first
90 days following such 211th day and at a rate of 0.5% per annum
thereafter; or

     (iii) if the Company or any Guarantor has failed to perform its obligations set
forth in Section 2(c) hereof within the time periods required therein, then
commencing on the first day after the date by which the Company or any Guarantor was
required to perform such obligations, Additional Interest shall accrue on the
principal amount of the outstanding Notes at a rate of 0.25% per annum for the first
90 days and at a rate of 0.5% per annum thereafter;

     (iv) if the Shelf Registration Statement has been declared effective but such
Shelf Registration Statement ceases to be effective at any time during the

6

 

Effective Period (other than pursuant to Section 3(b) hereof), then commencing on the day such
Shelf Registration Statement ceases to be effective, Additional Interest shall
accrue on the principal amount of the outstanding Notes at a rate of 0.25% per annum
for the first 90 days following such date on which the Shelf Registration Statement
ceases to be effective and at a rate of 0.5% per annum thereafter; or

     (v) if the aggregate duration of Deferral Periods in any period exceeds the
number of days permitted in respect of such period pursuant to Section 3(b) hereof,
then commencing on the day the aggregate duration of Deferral Periods in any period
exceeds the number of days permitted in respect of such period (and again on the
first day of any subsequent Deferral Period during such period), Additional Interest
shall accrue on the principal amount of the outstanding Notes that are Registrable
Securities at a rate of 0.25% per annum for the first 90 days and at a rate of 0.5%
per annum thereafter;

provided, however, that the Additional Interest rate on the Notes shall not exceed in the
aggregate 0.5% per annum and shall not be payable under more than one clause above for any
given period of time, except that if Additional Interest would be payable under more than
one clause above, but at a rate of 0.25% per annum under one clause and at a rate of 0.5%
per annum under the other, then the Additional Interest rate shall be the higher rate of
0.5% per annum; provided further, however, that (1) upon the filing of the Shelf
Registration Statement (in the case of clause (i) above), (2) upon the effectiveness of the
Shelf Registration Statement (in the case of clause (ii) above), (3) upon the performance by
the Company and each Guarantor of their obligations set forth in Section 2(c) hereof within
the time periods required therein (in the case of clause (iii) above), (4) upon the
effectiveness of the Shelf Registration Statement which had ceased to remain effective (in
the case of clause (iv) above), (5) upon the termination of the Deferral Period that caused
the limit on the aggregate duration of Deferral Periods in a period set forth in Section
3(b) to be exceeded (in the case of clause (v) above), (6) upon the termination of certain
transfer restrictions on the Securities as a result of the application of Rule 144(k) or any
successor provision or (7) for any period after the second anniversary from the Closing
Date, Additional Interest on the Notes as a result of such clause, as the case may be, shall
cease to accrue.

       Additional Interest on the Notes, if any, will be payable in cash on February 15 and
August 15 of each year (the “Additional Interest Payment Date”) to holders of record of
outstanding Notes that are Registrable Securities at the close of business on February 1 or
August 1, as the case may be, immediately preceding the relevant interest payment date,
provided that in the case of an event of the type described in clause (iii) above, such
Additional Interest shall be paid only to the Holders that have delivered Notice and
Questionnaires that caused the Company and the Guarantors to incur the obligations set forth
in Section 2(c), the non-performance of which is the basis of such Registration Default;
provided further that any Additional Interest accrued with respect to any Notes or portion
thereof called for redemption on a redemption date or

7

 

converted into Shares on a conversion
date prior to the Registration Default shall, in any such event, be paid instead to the
Holder who submitted such Notes or portion thereof for redemption or conversion on the
applicable redemption date or conversion date, as the case may be, on such date (or promptly
following the conversion date, in the case of conversion). Following the cure of all
Registration Defaults requiring the payment of Additional Interest to the Holders of Notes
that are Registrable Securities pursuant to this Section, the accrual of Additional Interest
will cease (without in any way limiting the
effect of any subsequent Registration Default requiring the payment of Additional Interest).

       The Company and each Guarantor shall notify the Trustee immediately upon the happening
of each and every Registration Default. The Trustee shall be entitled, on behalf of Holders
of Securities, to seek any available remedy for the enforcement of this Agreement, including
for the payment of any Additional Interest. Notwithstanding the foregoing, the parties
agree that the sole monetary damages payable for a violation of the terms of this Agreement
with respect to which additional monetary amounts are expressly provided shall be as set
forth in this Section 2(d). Nothing shall preclude a Notice Holder or Holder of Registrable
Securities from pursuing or obtaining specific performance or other equitable relief with
respect to this Agreement.

     3. Registration Procedures.

     The following provisions shall apply to the Shelf Registration Statement filed pursuant to
Section 2:

     (a) The Company and each Guarantor shall:

     (i) prepare and file with the Commission a registration statement with respect
to the shelf registration on any form which may be utilized by the Company and which
shall permit the disposition of the Registrable Securities in accordance with the
intended method or methods thereof, as specified in writing by the Holders of the
Registrable Securities, and use its reasonable best efforts to cause such
registration statement to become effective in accordance with Section 2(a) above;

     (ii) before filing any Shelf Registration Statement or Prospectus or any
amendments or supplements thereto with the Commission, furnish to the Initial
Purchaser copies of all such documents proposed to be filed and use reasonable best
efforts to reflect in each such document when so filed with the Commission such
comments as the Initial Purchaser reasonably shall propose within three (3) Business
Days of the delivery of such copies to the Initial Purchaser;

     (iii) use its reasonable best efforts to prepare and file with the Commission
such amendments and post-effective amendments to the Shelf Registration Statement
and file with the Commission any other required document as may be necessary to keep
such Shelf Registration Statement continuously

8

 

effective until the expiration of the
Effective Period; cause the related Prospectus to be supplemented by any required
prospectus supplement, and as so supplemented to be filed pursuant to Rule 424 (or
any similar provisions then in force) under the Securities Act; and comply with the
provisions of the Securities Act applicable to it with respect to the disposition of
all Securities covered by such Shelf Registration Statement during the Effective
Period in accordance with the intended methods of disposition by the sellers thereof
set forth in such Shelf Registration Statement as so amended or such Prospectus as
so supplemented;

     (iv) promptly notify the Notice Holders of Registrable Securities (A) when such
Shelf Registration Statement or the Prospectus included therein or any amendment or
supplement to the Prospectus or post-effective amendment has been filed with the
Commission, and, with respect to such Shelf Registration Statement or any
post-effective amendment, when the same has become effective, (B) of any request,
following the effectiveness of the Shelf Registration Statement, by the Commission
or any other Federal or state governmental authority for amendments or supplements
to the Shelf Registration Statement or related Prospectus or for additional
information, (C) of the issuance by the Commission of any stop order suspending the
effectiveness of such Shelf Registration Statement or the initiation or written
threat of any proceedings for that purpose, (D) of the receipt by the Company or any
Guarantor of any notification with respect to the suspension of the qualification of
the Registrable Securities for sale in any jurisdiction or the initiation or written
threat of any proceeding for such purpose, (E) of the occurrence of (but not the
nature of or details concerning) any event or the existence of any fact (a “Material
Event”) as a result of which any Shelf Registration Statement shall contain any
untrue statement of a material fact or omit to state any material fact required to
be stated therein or necessary to make the statements therein not misleading, or any
Prospectus shall contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to make the statements
therein, in the light of the circumstances under which they were made, not
misleading (provided, however, that no notice by the Company shall be required
pursuant to this clause (E) in the event that the Company either promptly files a
prospectus supplement to update the Prospectus or a Form 8-K or other appropriate
Exchange Act report that is incorporated by reference into the Shelf Registration
Statement, which, in either case, contains the requisite information with respect to
such Material Event that results in such Shelf Registration Statement no longer
containing any untrue statement of material fact or omitting to state a material
fact necessary to make the statements contained therein not misleading), (F) of the
determination by the Company that a post-effective amendment to the Shelf
Registration Statement will be filed with the Commission, which notice may, at the
discretion of the Company (or as required pursuant to Section 3(b)), state that it
constitutes a Deferral Notice, in which event the provisions of Section 3(b) shall
apply or (G) at any time when a Prospectus is required to be delivered under the
Securities Act, that the Shelf Registration

9

 

Statement, Prospectus, Prospectus
amendment or supplement or post-effective amendment does not conform in all material
respects to the applicable requirements of the Securities Act and the Trust
Indenture Act and the rules and regulations of the Commission thereunder;

     (v) prior to any public offering of the Registrable Securities pursuant to the
Shelf Registration Statement, use its reasonable best efforts to register or
qualify, or cooperate with the Notice Holders of Securities included therein and
their respective counsel in connection with the registration or qualification of,
such Securities for offer and sale under the securities or blue sky laws of such
jurisdictions as any such Notice Holders reasonably requests in writing and do
any and all other acts or things necessary or advisable to enable the offer and sale
in such jurisdictions of the Securities covered by the Shelf Registration Statement;
prior to any public offering of the Registrable Securities pursuant to the Shelf
Registration Statement, use its reasonable best efforts to keep each such
registration or qualification (or exemption therefrom) effective during the
Effective Period in connection with such Notice Holder’s offer and sale of
Registrable Securities pursuant to such registration or qualification (or exemption
therefrom) and do any and all other acts or things necessary or advisable to enable
the disposition in such jurisdictions of such Registrable Securities in the manner
set forth in the Shelf Registration Statement and the related Prospectus; provided
that the Company will not be required to qualify generally to do business in any
jurisdiction where it is not then so qualified or to take any action which would
subject it to general service of process or to taxation in any such jurisdiction
where it is not then so subject;

     (vi) use its reasonable best efforts to prevent the issuance of, and if issued,
to obtain the withdrawal of any order suspending the effectiveness of the Shelf
Registration Statement or any post-effective amendment thereto, and to lift any
suspension of the qualification of any of the Registrable Securities for sale in any
jurisdiction in which they have been qualified for sale, in each case at the
earliest practicable date;

     (vii) upon reasonable notice, for a reasonable period prior to the filing of
the Shelf Registration Statement, and throughout the Effective Period, (i) make
reasonably available for inspection by a representative of, and Special Counsel
acting for, Majority Holders of the Securities being sold and any underwriter (and
its counsel) participating in any disposition of Securities pursuant to such Shelf
Registration Statement, all relevant financial and other records, pertinent
corporate documents and properties of the Company and its subsidiaries and (ii) use
reasonable best efforts to have their officers, directors, employees, accountants
and counsel supply all relevant information reasonably requested by such
representative, Special Counsel or any such underwriter in connection with such
Shelf Registration Statement;

10

 

     (viii) if requested by Majority Holders of the Securities being sold in an
underwriting, its Special Counsel or the managing underwriters (if any) in
connection with such Shelf Registration Statement, use its reasonable best efforts
to cause (i) its counsel to deliver an opinion relating to the Shelf Registration
Statement and the Securities in customary form, (ii) its officers to execute and
deliver all customary documents and certificates requested by the Majority Holders
of the Securities being sold, their Special Counsel or the managing underwriters (if
any) and (iii) its independent public accountants to provide a comfort letter or
letters in customary form, subject to receipt of appropriate documentation as
contemplated, and only if permitted, by Statement of Auditing Standards No. 72;

     (ix) if reasonably requested by the Initial Purchaser or any Notice Holder,
promptly incorporate in a prospectus supplement or post-effective amendment to the
Shelf Registration Statement such information as the Initial Purchaser or such
Notice Holder shall, on the basis of a written opinion of nationally-recognized
counsel experienced in such matters, determine to be required to be included therein
by applicable law and make any required filings of such prospectus supplement or
such post-effective amendment; provided, that the Company shall not be required to
take any actions under this Section 3(a)(ix) that are not, in the reasonable opinion
of counsel for the Company, in compliance with applicable law;

     (x) promptly furnish to each Notice Holder and the Initial Purchaser, upon
their request and without charge, at least one (1) conformed copy of the Shelf
Registration Statement and any amendments thereto, including financial statements
but excluding schedules, all documents incorporated or deemed to be incorporated
therein by reference and all exhibits; provided, however, that the Company shall
have no obligation to deliver to Notice Holders or the Initial Purchaser a copy of
any amendment consisting exclusively of an Exchange Act report or other Exchange Act
filing otherwise publicly available on the Company’s website;

     (xi) during the Effective Period, deliver to each Notice Holder in connection
with any sale of Registrable Securities pursuant to the Shelf Registration
Statement, without charge, as many copies of the Prospectus relating to such
Registrable Securities (including each preliminary prospectus) and any amendment or
supplement thereto as such Notice Holder may reasonably request; and the Company
hereby consents (except during such periods that a Deferral Notice is outstanding
and has not been revoked) to the use of such Prospectus or each amendment or
supplement thereto by each Notice Holder in connection with any offering and sale of
the Registrable Securities covered by such Prospectus or any amendment or supplement
thereto in the manner set forth therein; and

     (xii) cooperate with the Notice Holders of Securities to facilitate the timely
preparation and delivery of certificates representing Securities to be sold

11

 

pursuant to the Shelf Registration Statement free of any restrictive legends and in such
denominations and registered in such names as the Holders thereof may request in
writing at least two business days prior to sales of Securities pursuant to such
Shelf Registration Statement.

     (b) Upon (A) the issuance by the Commission of a stop order suspending the
effectiveness of the Shelf Registration Statement or the initiation of proceedings with
respect to the Shelf Registration Statement under Section 8(d) or 8(e) of the Securities
Act, (B) the occurrence of any event or the existence of any Material Event as a result of
which the Shelf Registration Statement shall contain any untrue statement of a material fact
or omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading, or any Prospectus shall contain any untrue statement of a
material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading, or (C) the occurrence or existence of any corporate
development that, in the discretion of the Company, makes it appropriate to suspend the
availability of the Shelf Registration Statement and the related Prospectus, the Company
will (i) in the case of clause (B) above, subject to the third sentence of this provision,
as promptly as practicable prepare and file a post-effective amendment to such Shelf
Registration Statement or a supplement to the related Prospectus or any document
incorporated therein by reference or file any other required document that would be
incorporated by reference into such Shelf Registration Statement and Prospectus so that such
Shelf Registration Statement does not contain any untrue statement of a material fact or
omit to state any material fact required to be stated therein or necessary to make the
statements therein not misleading, and such Prospectus does not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or
necessary to make the statements therein, in the light of the circumstances under which they
were made, not misleading, as thereafter delivered to the purchasers of the Registrable
Securities being sold thereunder, and, in the case of a post-effective amendment to the
Shelf Registration Statement, subject to the third sentence of this provision, use
reasonable best efforts to cause it to be declared effective as promptly as is practicable,
and (ii) give notice to the Notice Holders that the availability of the Shelf Registration
Statement is suspended (a “Deferral Notice”). Upon receipt of any Deferral Notice, each
Notice Holder agrees not to sell any Registrable Securities pursuant to the Shelf
Registration Statement until such Notice Holder’s receipt of copies of the supplemented or
amended Prospectus provided for in clause (i) above, or until it is advised in writing by
the Company that the Prospectus may be used, and has received copies of any additional or
supplemental filings that are incorporated or deemed incorporated by reference in such
Prospectus. The Company and each Guarantor will use its reasonable best efforts to ensure
that the use of the Prospectus may be resumed (x) in the case of clause (A) above, as
promptly as practicable, (y) in the case of clause (B) above, as soon as, in the sole
judgment of the Company, public disclosure of such Material Event would not be prejudicial
to or contrary to the interests of the Company or, if necessary to avoid unreasonable burden
or expense, as soon as practicable thereafter and (z) in the case of clause (C) above, as
soon as, in the discretion of the Company, such

12

 

suspension is no longer appropriate;
provided that the period during which the availability of the Shelf Registration Statement
and any Prospectus is suspended (the “Deferral Period”), without the Company incurring any
obligation to pay Additional Interest pursuant to Section 2(d), shall not exceed one hundred
and twenty (120) days in the aggregate in any twelve (12) month period.

     (c) Each Holder of Registrable Securities agrees that upon receipt of any Deferral
Notice from the Company, such Holder shall forthwith discontinue (and cause any placement or
sales agent or underwriters acting on their behalf to discontinue) the disposition of
Registrable Securities pursuant to the registration statement applicable to such Registrable
Securities until such Holder (i) shall have received copies of such amended or supplemented
Prospectus and, if so directed by the Company, such Holder shall deliver to the Company (at
the Company’s expense) all copies, other than permanent file copies, then in such Holder’s
possession of the Prospectus covering such Registrable
Securities at the time of receipt of such notice or (ii) shall have received notice
from the Company that the disposition of Registrable Securities pursuant to the Shelf
Registration may continue.

     (d) The Company may require each Holder of Registrable Securities as to which any
registration pursuant to Section 2(a) is being effected to furnish to the Company such
information regarding such Holder and such Holder’s intended method of distribution of such
Registrable Securities as the Company may from time to time reasonably request in writing,
but only to the extent that such information is required in order to comply with the
Securities Act. Each such Holder agrees to notify the Company as promptly as practicable of
any inaccuracy or change in information previously furnished by such Holder to the Company
or of the occurrence of any event in either case as a result of which any Prospectus
relating to such registration contains or would contain an untrue statement of a material
fact regarding such Holder or such Holder’s intended method of disposition of such
Registrable Securities or omits to state any material fact regarding such Holder or such
Holder’s intended method of disposition of such Registrable Securities required to be stated
therein or necessary to make the statements therein not misleading, and promptly to furnish
to the Company any additional information required to correct and update any previously
furnished information or required so that such Prospectus shall not contain, with respect to
such Holder or the disposition of such Registrable Securities, an untrue statement of a
material fact or omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading.

     (e) The Company and each Guarantor shall comply with all applicable rules and
regulations of the Commission and make generally available to its securityholders earning
statements (which need not be audited) satisfying the provisions of Section 11(a) of the
Securities Act and Rule 158 thereunder (or any similar rule promulgated under the Securities
Act) no later than 40 days after the end of any 12-month period (or 75 days after the end of
any 12-month period if such period is a fiscal year) commencing on the first day of the
first fiscal quarter of the Company commencing after the effective date of the Shelf
Registration Statement, which statements shall cover said 12-month periods.

13

 

     (f) The Company shall provide a CUSIP number for all Registrable Securities covered by
the Shelf Registration Statement not later than the effective date of such Shelf
Registration Statement and provide the Trustee for the Notes and the transfer agent for the
Shares with printed certificates for the Registrable Securities that are in a form eligible
for deposit with The Depository Trust Company.

     (g) The Company and each Guarantor shall use its reasonable best efforts to provide
such information as is required for any filings required to be made with the National
Association of Securities Dealers, Inc.

     (h) Until the expiration of the Effectiveness Period, the Company will not, and will
not permit any of its “affiliates” (as defined in Rule 144) to, resell any of the Securities
that have been reacquired by any of them except pursuant to an effective registration
statement under the Securities Act.

     (i) The Company and each of the Guarantors shall cause the Indenture to be qualified
under the Trust Indenture Act in a timely manner.

     (j) The Company shall enter into such customary agreements and take all such other
necessary and lawful actions in connection therewith (including those requested by the
Majority Holders of the Registrable Securities being sold) in order to expedite or
facilitate disposition of such Registrable Securities.

     4. Holder’s Obligations.

     Each Holder agrees, by acquisition of the Registrable Securities, that no Holder of
Registrable Securities shall be entitled to sell any of such Registrable Securities pursuant to the
Shelf Registration Statement or to receive a Prospectus relating thereto, unless such Holder has
furnished the Company with a Notice and Questionnaire as required pursuant to Section 2(c) hereof
(including the information required to be included in such Notice and Questionnaire) and the
information set forth in the next sentence. Each Notice Holder agrees promptly to furnish to the
Company all information required to be disclosed in order to make the information previously
furnished to the Company by such Notice Holder not misleading and any other information regarding
such Notice Holder and the distribution of such Registrable Securities as may be required to be
disclosed in the Shelf Registration Statement under applicable law or pursuant to Commission
comments. Each Holder further agrees not to sell any Registrable Securities pursuant to the Shelf
Registration Statement without delivering, or causing to be delivered, a Prospectus to the
purchaser thereof and, following termination of the Effective Period, to notify the Company, within
10 Business Days of a request by the Company, of the amount of Registrable Securities sold pursuant
to the Shelf Registration Statement and, in the absence of a response, the Company may assume that
all of the Holder’s Registrable Securities were so sold.

14

 

     5. Registration Expenses.

     The Company and each Guarantor agrees to bear and to pay or cause to be paid promptly upon
request being made therefor all expenses incident to the Company’s performance of or compliance
with this Agreement, including, but not limited to, (a) all Commission and any NASD registration
and filing fees and expenses, (b) all fees and expenses in connection with the qualification of the
Securities for offering and sale under the State securities and Blue Sky laws referred to in
Section 3(a)(v) hereof, including reasonable fees and disbursements of one counsel for the
placement agent or underwriters, if any, in connection with such qualifications, (c) all expenses
relating to the preparation, printing, distribution and reproduction of the Shelf Registration
Statement, the related Prospectus, each amendment or supplement to each of the foregoing, the
certificates representing the Securities and all other documents relating hereto, (d) fees and
expenses of the Trustee under the Indenture, any escrow agent or custodian, and of the registrar
and transfer agent for the Shares, (e) fees, disbursements and expenses of counsel and independent
certified public accountants of the Company (including the expenses of any reports required by the
Securities Act or the rules and regulations thereunder to be included or incorporated by reference
in the Shelf Registration Statement or “cold comfort” letters required by or incident to such
performance and compliance) and (f) reasonable fees, disbursements and expenses of one counsel for
the Holders of Registrable Securities retained in connection with the
Shelf Registration Statement, as selected by the Company (unless reasonably objected to by the
Majority Holders of the Registrable Securities being registered, in which case the Majority Holders
shall select such counsel for the Holders)(“Special Counsel”), and fees, expenses and disbursements
of any other Persons, including special experts, retained by the Company in connection with such
registration (collectively, the “Registration Expenses”). To the extent that any Registration
Expenses are incurred, assumed or paid by any Holder of Registrable Securities or any underwriter
or placement agent therefor, the Company shall reimburse such Person for the full amount of the
Registration Expenses so incurred, assumed or paid promptly after receipt of a documented request
therefor. Notwithstanding the foregoing, the Holders of the Registrable Securities being
registered shall pay all underwriting discounts and commissions and placement agent fees and
commissions attributable to the sale of such Registrable Securities and the fees and disbursements
of any counsel or other advisors or experts retained by such Holders (severally or jointly), other
than the counsel and experts specifically referred to above.

     6. Indemnification.

     (a) The Company and each Guarantor agrees to indemnify and hold harmless each Holder
(including, without limitation, the Initial Purchaser), the directors, officers, employees
and Affiliates of the Initial Purchaser and each person who controls such Holder within the
meaning of either the Act or the Exchange Act against any and all losses, claims, damages or
liabilities, joint or several, to which they or any of them may become subject under the
Act, the Exchange Act or other federal or state statutory law or regulation, at common law
or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon any untrue statement or alleged untrue statement of
a material fact contained in any such Registration Statement or any prospectus forming part
thereof or in any amendment or

15

 

supplement thereto, or arise out of or are based upon the
omission or alleged omission to state therein a material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which
they were made, not misleading, and agrees to reimburse each such indemnified party, as
incurred, for any legal or other expenses reasonably incurred by it in connection with
investigating or defending any such loss, claim, damage, liability or action; provided,
however, that neither the Company nor any Guarantor will not be liable in any such case to
the extent that any such loss, claim, damage or liability arises out of or is based upon any
such untrue statement or alleged untrue statement or omission or alleged omission from any
such document, in reliance upon and in conformity with written information provided by a
Holder in its most recent Notice and Questionnaire; provided further, that with respect to
any untrue statement or omission of material fact from any related preliminary prospectus,
the indemnity agreement contained in this Section 6(a) shall not inure to the benefit of any
Holder from whom the Person asserting any such loss, claim, damage or liability purchased
the securities concerned, to the extent that any such loss, claim, damage or liability of
such Holder occurs under the circumstance that (y) the untrue statement or omission of a
material fact from the related preliminary prospectus was corrected in the final prospectus
unless, in either case, such failure to deliver the final Prospectus was a result of
non-compliance by the Company with Section 3 and (z) there was not sent or given to such
Person, at or prior to the written confirmation of the sale of
such securities to such Person, a copy of the final prospectus. This indemnity
agreement will be in addition to any liability that the Company or any Guarantor may
otherwise have.

     (b) Each Holder agrees to indemnify and hold harmless the Company, each Guarantor, each
of its directors, each of its officers, and each person, if any, who controls the Company or
any Guarantor within the meaning of either the Act or the Exchange Act, against any and all
losses, claims, damages or liabilities, joint or several, to which the Company or any
Guarantor may become subject under the Act, the Exchange Act or other federal or state
statutory law or regulation, at common law or otherwise, insofar as such losses, claims,
damages or liabilities (or actions in respect thereof) arise out of or are based upon any
untrue statement or alleged untrue statement of a material fact contained in any such
Registration Statement or any prospectus forming part thereof or in any amendment or
supplement thereto, or arise out of or are based upon the omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they were made, not
misleading, but in each case only to the extent that the untrue statement or alleged untrue
statement or omission or alleged omission was made in reliance upon and in conformity with
any information furnished to the Company by such Holder in its most recent Notice and
Questionnaire, and agrees to reimburse the Company, as incurred, for any legal or other
expenses reasonably incurred by it in connection with investigating or defending any such
loss, claim, damage, liability or action provided, however, that no such Holder shall be
liable for any indemnity claims hereunder in excess of the amount of net proceeds received
by such Holder from the sale of Securities pursuant to such Shelf

16

 

Registration Statement.
This indemnity agreement will be in addition to any liability which any such Holder may
otherwise have.

     (c) Promptly after receipt by an indemnified party under this Section 6 of notice of
the commencement of any action, such indemnified party will, if a claim in respect thereof
is to be made against the indemnifying party under this Section 6, notify the indemnifying
party in writing of the commencement thereof; but the failure so to notify the indemnifying
party (i) will not relieve it from liability under paragraph (a) or (b) above unless and to
the extent it has been materially prejudiced through the forfeiture by the indemnifying
party of substantial rights and defenses and (ii) will not, in any event, relieve the
indemnifying party from any obligations to any indemnified party other than the
indemnification obligation provided in paragraph (a) or (b). If any action shall be brought
against an indemnified party and it shall have notified the indemnifying party thereof, the
indemnifying party shall be entitled to appoint counsel (including local counsel) of the
indemnifying party’s choice at the indemnifying party’s expense to represent the indemnified
party in any action for which indemnification is sought (in which case the indemnifying
party shall not thereafter be responsible for the fees and expenses of any separate counsel,
other than local counsel if not appointed by the indemnifying party, retained by the
indemnified party or parties except as set forth below); provided, however, that such
counsel shall be reasonably satisfactory to the indemnified party. Notwithstanding the
indemnifying party’s election to appoint counsel (including local counsel) to represent the
indemnified party in an action, the indemnified party shall have the right to employ separate counsel (including local counsel), and
the indemnifying party shall bear the reasonable fees, costs and expenses of such separate
counsel if (i) the use of counsel chosen by the indemnifying party to represent the
indemnified party would present such counsel with a conflict of interest; (ii) the actual or
potential defendants in, or targets of, any such action include both the indemnified party
and the indemnifying party and the indemnified party shall have reasonably concluded that
there may be legal defenses available to it and/or other indemnified parties that are
different from or additional to those available to the indemnifying party; (iii) the
indemnifying party shall not have employed counsel reasonably satisfactory to the
indemnified party to represent the indemnified party within a reasonable time after notice
of the institution of such action; or (iv) the indemnifying party shall authorize the
indemnified party to employ separate counsel at the expense of the indemnifying party. An
indemnifying party will not, without the prior written consent of the indemnified parties,
settle or compromise or consent to the entry of any judgment with respect to any pending or
threatened claim, action, suit or proceeding in respect of which indemnification or
contribution may be sought hereunder (whether or not the indemnified parties are actual or
potential parties to such claim or action) unless such settlement, compromise or consent
includes an unconditional release of each indemnified party from all liability arising out
of such claim, action, suit or proceeding and does not include an admission of fault,
culpability or a failure to act, by or on behalf of such indemnified party.

17

 

     (d) The provisions of this Section 6 and Section 7 shall remain in full force and
effect, regardless of any investigation made by or on behalf of any Holder, the Company, or
any of the indemnified Persons referred to in this Section 6 and Section 7, and shall
survive the sale by a Holder of securities covered by the Shelf Registration Statement.

          7. Contribution.

     If the indemnification provided for in Section 6 is unavailable or insufficient to hold
harmless an indemnified party under Section 6(a) or 6(b), then each indemnifying party shall, in
lieu of indemnifying such indemnified party, contribute to the amount paid or payable by such
indemnified party as a result of such loss, claim, damage or liability, or action in respect
thereof, (i) in such proportion as shall be appropriate to reflect the relative benefits received
by the Company from the offering and sale of the Notes, on the one hand, and a Holder with respect
to the sale by such Holder of Securities, on the other, or (ii) if the allocation provided by
clause (i) above is not permitted by applicable law, in such proportion as is appropriate to
reflect not only the relative benefits referred to in clause (i) above but also the relative fault
of the Company and the Guarantors on the one hand and such Holder on the other with respect to the
statements or omissions that resulted in such loss, claim, damage or liability, or action in
respect thereof, as well as any other relevant equitable considerations. The relative benefits
received by the Company and the Guarantors on the one hand and a Holder on the other with respect
to such offering and such sale shall be deemed to be in the same proportion as the total net
proceeds from the offering of the Notes (excluding discounts and commissions, but before deducting
expenses) received by or on behalf of the Company and the Guarantors, on the one hand, and the
total net proceeds (excluding discounts and commissions, but before deducting expenses) received by
such Holder upon a resale of the Securities, on the other, bear to the total gross
proceeds from the sale all Securities pursuant to the Shelf Registration Statement in the offering
of the Securities from which the contribution claim arises. The relative fault shall be determined
by reference to, among other things, whether the untrue or alleged untrue statement of a material
fact or the omission or alleged omission to state a material fact relates to the Company and the
Guarantors or information supplied by the Company and the Guarantors on the one hand or to any
information contained in the relevant Notice and Questionnaire supplied by such Holder on the
other, the intent of the parties and their relative knowledge, access to information and
opportunity to correct or prevent such untrue statement or omission. The parties hereto agree that
it would not be just and equitable if contributions pursuant to this Section 7 were to be
determined by pro rata allocation or by any other method of allocation that does not take into
account the equitable considerations referred to herein. The amount paid or payable by an
indemnified party as a result of the loss, claim, damage or liability, or action in respect
thereof, referred to above in this Section 7 shall be deemed to include, for purposes of this
Section 7, any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating or defending or preparing to defend any such action or claim. Notwithstanding
the provisions of this Section 7, an indemnifying party that is a Holder of Securities shall not be
required to contribute any amount in excess of the amount by which the total price at which the
Securities sold by such indemnifying party to any purchaser exceeds the amount of any damages which
such indemnifying party has otherwise paid or become liable to pay by reason of any untrue or
alleged untrue statement or omission or alleged omission. No person guilty of

18

 

fraudulent
misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation.

     8. Rule 144A and Rule 144.

     So long as any Registrable Securities remain outstanding, the Company and each of the
Guarantors shall use its reasonable best efforts to file the reports required to be filed by it
under Rule 144A(d)(4) under the Securities Act and the Exchange Act in a timely manner and, if at
any time the Company and each of the Guarantors is not required to file such reports, it will, upon
the written request of any Holder of Restricted Securities, make publicly available other
information so long as necessary to permit sales of such Holder’s securities pursuant to Rules 144
and 144A. The Company and each of the Guarantors covenants that it will take such further action
as any Holder of Restricted Securities may reasonably request, all to the extent required from time
to time to enable such Holder to sell Registrable Securities without registration under the
Securities Act within the limitation of the exemptions provided by Rules 144 and 144A (including,
without limitation, the requirements of Rule 144A(d)(4)). Upon the written request of any Holder
of Registrable Securities, the Company shall deliver to such Holder a written statement as to
whether it and each of the Guarantors has complied with such requirements. Notwithstanding the
foregoing, nothing in this Section 8 shall be deemed to require the Company or any of the
Guarantors to register any of its securities pursuant to the Exchange Act.

     9. Miscellaneous.

               (a) Amendments and Waivers. The provisions of this Agreement may not be amended,
modified or supplemented, and waivers or consents to departures from the provisions hereof may not
be given, unless the Company has obtained the written consent of the Majority
Holders. Notwithstanding the foregoing, a waiver or consent to depart from the provisions
hereof with respect to a matter that relates exclusively to the rights of Holders whose Securities
are being sold pursuant to the Shelf Registration Statement and that does not directly or
indirectly affect the rights of other Holders may be given by Holders of a majority in aggregate
amount of the Securities being sold by such Holders pursuant to the Shelf Registration Statement.

               (b) Notices. All notices and other communications provided for or permitted hereunder
shall be made in writing by hand-delivery, first-class mail, telecopier or air courier guaranteeing
next-day delivery:

     (1) If to the Company, initially at the address set forth in the Purchase
Agreement;

     (2) If to the Initial Purchaser, initially at the address set forth in the
Purchase Agreement; and

     (3) If to a Holder, to the address of such Holder set forth in the security
register, the Notice and Questionnaire or other records of the Company.

19

 

               All such notices and communications shall be deemed to have been duly given: when delivered by
hand, if personally delivered; one business day after being delivered to a next-day air courier;
five business days after being deposited in the mail; and when receipt is acknowledged by the
recipient’s telecopier machine, if sent by telecopier.

               (c) Successors and Assigns. This Agreement shall be binding upon the Company, each
Guarantor and each of their respective successors and assigns.

               (d) Counterparts. This Agreement may be executed in any number of counterparts (which
may be delivered in original form or by telecopier) and by the parties hereto in separate
counterparts, each of which when so executed shall be deemed to be an original and all of which
taken together shall constitute one and the same agreement.

               (e) Definition of Terms. For purposes of this Agreement, (a) the term “business day”
means any day on which the New York Stock Exchange, Inc. is open for trading, (b) the term
“subsidiary” has the meaning set forth in Rule 405 under the Securities Act and (c) except where
otherwise expressly provided, the term “affiliate” has the meaning set forth in Rule 405 under the
Securities Act.

               (f) Headings. The headings in this Agreement are for convenience of reference only
and shall not limit or otherwise affect the meaning hereof.

               (g) Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York.

               (h) Remedies. In the event of a breach by the Company or by any Holder of any of
their respective obligations under this Agreement, each Holder or the Company, as the case may be,
in addition to being entitled to exercise all rights granted by law, including recovery
of damages (other than the recovery of damages for a breach by the Company of its obligations
under Section 3 hereof for which Additional Interest have been paid pursuant to Section 2 hereof),
will be entitled to specific performance of its rights under this Agreement. The Company and each
Holder agree that monetary damages would not be adequate compensation for any loss incurred by
reason of a breach by it of any of the provisions of this Agreement and hereby further agree that,
in the event of any action for specific performance in respect of such breach, it shall waive the
defense that a remedy at law would be adequate.

               (i) No Inconsistent Agreements. The Company and each of the Guarantors represents,
warrants and agrees that (i) it has not entered into, shall not, on or after the date of this
Agreement, enter into any agreement that is inconsistent with the rights granted to the Holders in
this Agreement or otherwise conflicts with the provisions hereof, (ii) it has not previously
entered into any agreement which remains in effect granting any registration rights with respect to
any of its debt securities to any person and (iii) without limiting the generality of the
foregoing, without the written consent of the Majority Holders, it shall not grant to any Person
the right to request the Company to register any securities of the Company under the Securities Act
unless the rights so granted are not in conflict or inconsistent with the provisions of this
Agreement.

20

 

               (j) No Piggyback on Registrations. Neither the Company nor any of its security
holders (other than the Holders of Restricted Securities in such capacity) shall have the right to
include any securities of the Company in any Shelf Registration Statement other than Registrable
Securities.

               (k) Severability. The remedies provided herein are cumulative and not exclusive of
any remedies provided by law. If any term, provision, covenant or restriction of this Agreement is
held by a court of competent jurisdiction to be invalid, illegal, void or unenforceable, the
remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in
full force and effect and shall in no way be affected, impaired or invalidated, and the parties
hereto shall use their reasonable best efforts to find and employ an alternative means to achieve
the same or substantially the same result as that contemplated by such term, provision, covenant or
restriction. It is hereby stipulated and declared to be the intention of the parties that they
would have executed the remaining terms, provisions, covenants and restrictions without including
any of such that may be hereafter declared invalid, illegal, void or unenforceable.

               (l) Survival. The respective indemnities, agreements, representations, warranties and
each other provision set forth in this Agreement or made pursuant hereto shall remain in full force
and effect regardless of any investigation (or statement as to the results thereof) made by or on
behalf of any Holder of Registrable Securities, any director, officer or partner of such Holder,
any agent or underwriter or any director, officer or partner thereof, or any controlling person of
any of the foregoing, and shall survive delivery of and payment for the Registrable Securities
pursuant to the Purchase Agreement and the transfer and registration of Registrable Securities by
such Holder.

               (m) Securities Held by the Company, etc. Whenever the consent or approval of Holders
of a specified percentage of Securities is required hereunder, Securities held by the Company or
its affiliates (other than subsequent Holders of Securities if such subsequent Holders
are deemed to be affiliates solely by reason of their holdings of such Securities) shall not
be counted in determining whether such consent or approval was given by the Holders of such
required percentage.

21

 

               If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to us a counterpart hereof, whereupon this instrument will become a binding agreement among
the Company and the Initial Purchaser in accordance with its terms.

	 	 	 	 	 	 	 
	 	 	Very truly yours,	 	 
	 
	 	 	 	 	 	 
	 	 	THE COMPANY	 	 
	 
	 	 	 	 	 	 
	 	 	PIER 1 IMPORTS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Charles H. Turner	 	 
	 

	 	 	 	 	 	 
	 	 	Name:	 	Charles H. Turner
	 	 	Title:	 	Executive Vice President - Finance,
Chief 

Financial Officer and Treasurer
	 
	 	 	 	 	 	 
	 	 	THE GUARANTORS	 	 

	 	 	 	 	 	 	 
	 	 	PIER 1 ASSETS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Charles H. Turner	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Charles H. Turner
	 

	 	 	 	Title: Executive Vice President,
Chief 
          Financial Officer and Treasurer	 	 
	 
	 	 	 	 	 	 
	 	 	PIER 1 KIDS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Charles H. Turner	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Charles H. Turner	 	 
	 

	 	 	 	Title: Executive Vice President	 	 
	 
	 	 	 	 	 	 
	 	 	PIER 1 LICENSING, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Charles H. Turner	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Charles H. Turner	 	 
	 

	 	 	 	Title: Executive Vice President,
Chief
          Financial Officer and Treasurer	 	 

 

 

	 	 	 	 	 	 	 
	 	 	PIER 1 IMPORTS (U.S.), INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Charles H. Turner	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Charles H. Turner	 	 
	 

	 	 	 	Title: Executive Vice President
and
          Chief Financial Officer	 	 
	 
	 	 	 	 	 	 
	 	 	PIER 1 VALUE SERVICES, LLC	 	 

	 	 	 	 	 	 	 	 	 
	 	 	By:	 	Pier 1 Imports (U.S.), Inc.,	 	 
	 	 	 	 	its sole member and manager	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:	 	/s/ Charles H. Turner	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Name: Charles H. Turner	 	 
	 

	 	 	 	 	 	Title: Executive Vice

          President and Chief

          Financial Officer	 	 

	 	 	 	 	 	 	 
	 	 	PIER 1 HOLDINGS, INC.	 	 
	 
	 	 	 	 	 	 
	 

	 	By:	 	/s/ Charles H. Turner	 	 
	 

	 	 	 	 	 	 
	 

	 	 	 	Name: Charles H. Turner	 	 
	 

	 	 	 	Title: Executive Vice President and

           Chief Financial Officer	 	 
	 
	 	 	 	 	 	 
	 	 	PIER 1 SERVICES COMPANY,	 	 
	 	 	a Delaware statutory trust	 	 

	 	 	 	 	 	 	 	 	 
	 	 	By:	 	Pier 1 Holdings, Inc.,	 	 
	 	 	 	 	its managing trustee	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:	 	/s/ Charles H. Turner	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Name: Charles H. Turner	 	 
	 

	 	 	 	 	 	Title: Executive Vice

          President
and Chief
         
Financial Officer	 	 

 

 

Accepted: February 14, 2006

By: J.P. MORGAN SECURITIES INC.

	 	 	 	 	 	 	 	 	 
	 

	 	By:
	 	/s/ Santosh Sreenivasan	 	 
	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	Name:	 	Santosh Sreenivasan	 	 	 	 
	 

	 	Title:	 	Vice President<PAGE>
                                                                    Exhibit 10.2

                              SUBLICENSE AGREEMENT

                                     between

                               Novartis Pharma AG

                                       and

                          Vanda Pharmaceuticals, Inc.

----------
[*] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.
<PAGE>
SUBLICENSE AGREEMENT

THIS SUBLICENSE AGREEMENT effective as of the 4th day of June, 2004,
("Effective Date") between Vanda Pharmaceuticals, Inc., a corporation organized
and existing under the laws of the State of Delaware and having its principal
office at 47 Hulfish Street, Suite 310, Princeton, NJ 08542, The United States
("Vanda") and Novartis Pharma AG, a corporation organized under the laws of
Switzerland and having its principal office at Lichtstrasse 35, CH-4056 Basel,
Switzerland ("Novartis")

WITNESSETH THAT:

WHEREAS Novartis is the exclusive worldwide licensee of Titan Pharmaceuticals,
Inc. ("Titan") under a sublicense agreement between Novartis and Titan having an
Effective Date of 20th November, 1997 and as amended by two Amendments between
the parties dated 30th November 1998 and 10th April, 2001 (the "Titan
Agreement"); and
WHEREAS Titan is the exclusive worldwide licensee of Hoechst Marion Roussel Inc.
("HMRI") under a license agreement between Titan and HMRI having an Effective
Date of 31st December, 1996 (the "HMRI Agreement"); and
WHEREAS as a result of corporate restructuring, Aventis Pharmaceuticals Inc., a
corporation organized under the laws of the State of Delaware and with offices
at 200 Crossing Boulevard, Bridgewater, NJ 08807-0890 ("Aventis") acquired
substantially all of the tangible operating assets of HMRI and, as a result, the
HMRI Agreement has been assigned to Aventis; and
WHEREAS under such Titan Agreement and the Novartis Patents, Novartis has rights
with respect to certain patents and patent applications, identified in Appendix
A hereto, and know-how relating to a compound known as Iloperidone; and
WHEREAS Vanda desires to obtain certain exclusive licenses from Novartis under
the Titan Agreement and the Novartis Patents, and Novartis is willing to grant
to Vanda such licenses;

NOW, THEREFORE, in consideration of the covenants and obligations expressed
herein, and intending to be legally bound, the parties agree as follows:

                                  Page 2 of 59
<PAGE>
1. DEFINITIONS

1.1 "Affiliate" shall mean any corporation, firm, partnership or other entity,
whether de jure or de facto, which directly or indirectly owns, is owned by or
is under common ownership with a party to this Sublicense Agreement, to the
extent of more than fifty percent (50%) of the equity (or such lesser percentage
which is the maximum allowed to be owned by a foreign corporation in a
particular jurisdiction) having the power to direct the affairs of the entity
and any person, firm, partnership, corporation or other entity actually
controlled by, controlling or under common control with a party to this
Sublicense Agreement.

1.2 "Commercially Reasonable Efforts "shall mean efforts and resources [*] used
[*] for a product [*], taking into account the [*] marketplace, the [*], and
[*].

1.3 "Competitive Industry Standard Level" shall mean the level to which the
Product shall be marketed by or on behalf of Vanda, its Affiliates or
Sublicensees in the countries of the Territory where Patents are issued and
enforced with [*], in a manner [*].

1.4 "Compound" shall mean the chemical compound known as Iloperidone [*],
including any salts, hydrates, solvates, and/or stereoisomers thereof, and only
the metabolites listed in Appendix B hereto, including any salts, hydrates,
solvates and/or stereoisomers of such metabolites.

1.5 "EEA" shall mean the European Economic Area, which consists of the European
Union and Iceland, Liechtenstein and Norway.

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 3 of 59
<PAGE>
1.6 "European Union" shall mean the member states of the European Union, as may
exist from time to time, which as of the date hereof include Austria, Belgium,
Denmark, Finland, France, Germany, Greece, Ireland, Italy, Luxembourg, the
Netherlands, Portugal, Spain, Sweden and the United Kingdom and all other
countries which accede to the European Union during the term of this Sublicense
Agreement.

1.7 "Exclusive" shall have the meaning specified in Section 2.1 hereof.

1.8 "FDA" shall mean the United States Food and Drug Administration.

1.9 "FD&C Act" shall mean the Federal Food, Drug and Cosmetic Act (21 U.S.C.
301ff), as amended from time to time.

1.10 "Field" shall mean application to all conditions, disorders and diseases in
humans.

1.11 "IND" shall mean an Investigational New Drug Application.

1.12 "Know-How" shall mean all technical information and know-how: (a) presently
developed and owned or controlled by HMRI or Titan and their Affiliates and made
available to Novartis, (b) developed and owned or controlled by Novartis and its
Affiliates after the date of the Titan Agreement, and (c) developed and owned or
controlled by HMRI, Titan or Novartis and their respective Affiliates, after the
date hereof and included within this definition of "Know-How" by operation of
Section 2.3 hereof, which relates to the Compound or Product in the Field and
which constitutes a proprietary "trade secret" or other valid intellectual
property right under U.S. or other applicable law which is substantial, secret
and identifiable, including, without limitation, all biological, chemical,
pharmacological, toxicological, clinical, regulatory, analytical, quality
control and manufacturing data and any other information (whether technical or
commercial) relating to the Compound or Product that may be useful for the
development, regulatory approval, manufacture and commercialization of the
Compound or Product.

1.13 "Major Market Country" shall mean each of [*].

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 4 of 59
<PAGE>
1.14 "NDA" shall mean any and all applications (new drug applications) submitted
to the FDA under Sections 505, 507 or 512 of the FD&C Act and applicable
regulations related to the Product, including without limitation, full NDAs,
"paper" NDAs and abbreviated NDAs (ANDAs) and all amendments and supplements
thereto or equivalent applications in the European Union.

1.15 "Net Sales" shall be calculated as follows: From the [*] price of the
Product sold by Vanda or its Affiliates or Sub-licensees [*] there shall be
subtracted, if not previously deducted in the amount invoiced or received, (i)
[*], (ii) [*], (iii) [*], (iv) [*], (v) [*], (vi) [*] and (vii) [*]. The
computation of Net Sales shall not include [*]. For the purposes of this
Sublicense Agreement, sales of the Product to [*] are considered to be sales to
third parties. If the Product is sold [*], royalties shall be due on Net Sales
to third parties [*]. It is agreed that there shall be [*]. In the event there
are sales of Compound to Third Parties [*] such sales shall be [*].
In the event that the Product is sold as part of a combination product, the Net
Sales of the Product, for the purposes of determining royalty payments, shall be
determined by

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 5 of 59
<PAGE>
[*] the Net Sales (as defined above in this Section) of [*]. In the event that
such [*] cannot be determined for both Product and the other product(s) in
combination, Net Sales for purposes of determining royalty payments shall be
mutually agreed by the parties within a reasonable period of time prior to the
first commercial sale of such combination product based on all relevant factors
including [*], and such agreement shall not be unreasonably withheld.

1.16 "Patents" shall mean all patents and patent applications set forth in
Appendix A, including continuations, continuations-in-part, divisions, patents
of addition, reissues, re-examinations, renewals or extensions thereof, along
with supplementary protection certificates and other administrative protection
of any kind in the Territory owned by or licensed to Novartis or its Affiliates
to the extent that such patents claim the Compound or Product, or use,
formulations or manufacture thereof, for use in the Field, but not any other
compound or use outside of the Field disclosed or claimed in those patents or
patent applications. Any Patent having claims covering the Compound or Product
or its use formulation and manufacture thereof for use in the Field which is
issued during the term of this Sublicense Agreement in any Country of the
Territory shall automatically be deemed as of the date of such issuance to be
included in the Patent, as defined hereunder.

1.17 "Product" shall mean any bulk or finished pharmaceutical composition
containing the Compound as a pharmaceutically active ingredient for use in the
Field, whether as a sole active ingredient or in combination with another active
ingredient.

1.18 "SEC" shall mean the United States Securities and Exchange Commission.

1.19 "Sub-licensee" shall mean a Third Party (as defined below) to whom a party
sub-licenses rights to manufacture and sell (or have manufactured and sold) the
Compound under Patents, but shall not include any Third Parties to whom rights
to manufacture the Compound have not been granted. Unless such party grants to
such Third Party the right to manufacture Compound, the following Third Parties
shall not be considered Sublicensees under this Sublicense Agreement: agents,
distributors, wholesalers, subcontractors, co-marketers, co-

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 6 of 59
<PAGE>
promoters, partners or joint venturers. Sub-licensees shall not include
compulsory licensees as described in Section 4.1(a).

1.20 "Territory" shall mean all countries and territories of the world provided
that any country(ies) in which this Sublicense Agreement is terminated shall be
removed from the scope of this definition.

1.21 "Third Party" shall mean any party other than a party to this Sublicense
Agreement, HMRI, Titan or an Affiliate of any of these.

2. GRANT

2.1 Novartis hereby grants to Vanda an Exclusive sublicense in the Field under
the Patents (to the extent, but only to the extent, that such patents or patent
applications claim the Compound or Product or the manufacture, formulation, or
use thereof) and Know-How to develop, have developed, make, have made, use,
import, sell, offer for sale and have sold the Compound and Product in the
Territory, subject to the terms and conditions of this Sub-license Agreement.
All rights granted by Novartis to Vanda in this Sublicense Agreement shall
remain subject to the rights and obligations of HMRI and Titan within the HMRI
Agreement. The sublicense granted to Vanda by Novartis shall include the right
of Vanda to sublicense its rights under this Sublicense Agreement, but only upon
Novartis', HMRI's and Titan's prior written consent, which consent shall not be
unreasonably withheld. Any such sublicensee(s) shall impose upon a
Sublicencee(s) of Vanda substantially the same terms and conditions as Vanda
assumes in this Sublicense Agreement. As used in this Sublicense Agreement, the
term "Exclusive" shall mean that neither Novartis, nor its Affiliates shall
grant any other license to, nor themselves exploit, the Patents and Know-How
with respect to the Compound and Product in the Field (unless otherwise
specified herein) and be limited as follows:
(a) With respect to all geographic areas outside of the EEA, such sublicense
shall be exclusive for the duration and validity of the intellectual property
rights constituting the Patents and/or Know-How.
(b) With respect to all geographic areas within the EEA, such sublicense shall
be exclusive for the following time periods:

                                  Page 7 of 59
<PAGE>
      (i) For each of the countries within the EEA where only Patents (and not
      Know-How) exist and are sublicensed to Vanda hereunder, the period of
      exclusivity for each such country shall be limited to the duration of the
      relevant Patents in such country, provided that "Patents" for the purposes
      of the interpretation of this paragraph shall be limited to patents
      existing, and patents issuing from patent applications existing, and
      patents issuing from patent applications covering inventions existing as
      of the date of the Titan Agreement;
      (ii) For each of the countries within the EEA where Patents and Know-How
      exist and are sublicensed to Vanda hereunder, the period of exclusivity
      for each such country shall be limited to the duration of the relevant
      Patents in such Country, provided that "Patents" for purposes of the
      interpretation of this paragraph shall be limited to patents existing, and
      patents issuing from patent applications existing, as of the date of the
      Titan Agreement and, provided, further, that if the duration of such
      Patents is less than ten (10) years from the date of first marketing of
      the Product in the EEA but the Know-How continues to be sublicensed
      hereunder, the duration of exclusivity shall be for ten (10) years from
      the date of first marketing of the Product in the EEA; and
      (iii) For each of the countries within the EEA where Know-How (and not
      Patents) exists and is sublicensed to Vanda hereunder, the period of
      exclusivity for each such country shall be limited to ten (10) years from
      the date of first marketing of the Product in the EEA. Thereafter, such
      sublicense within the EEA shall be on a non-exclusive basis.

(c) deleted

(d) Novartis and its Affiliates and licensed Third Parties and Sub-licensees
shall also be entitled to utilise the Patents and Know-How in the Field within
the Territory for the development and manufacture of the Compound and Product
for marketing, distribution and sale where Vanda's rights under this Sublicense
Agreement have been terminated. The duration of the sublicense granted by this
Section 2.1 shall be limited to the duration, on a country-by-country basis, of
the intellectual property rights which comprise the Patents and Know-How with
respect to a relevant country, provided that the termination of any portion of
any sublicense shall be without prejudice to the requirement of Vanda to pay
royalties pursuant to the terms of this Sublicense Agreement. Notwithstanding
the foregoing but subject to Sections 3.4 and 3.5 hereof, Novartis acknowledges
and agrees that Vanda shall have the right to continue to use on a royalty-free,
non-exclusive basis the information which

                                  Page 8 of 59
<PAGE>
constitutes the Patents and Know-How on a country-by-country basis in the
Territory for the Field after the Patents expire or cease to be valid or
enforceable and/or Know-How has entered into the public domain.

2.2 deleted

2.3 deleted.

2.4 Novartis grants to Vanda a non-exclusive, worldwide sublicense to make or
use any analytical reference standards, intermediate or metabolite of the
Compound or Product not listed in APPENDIX B hereto which may be claimed in
Patents limited solely to making or using the Compound or Product. [*]. Any
such sublicense shall [*].

2.5 Vanda shall promote, market and sell the Product under a registered
trademark(s) approved by HMRI, Titan and Novartis. Vanda will promptly inform
HMRI, Titan and Novartis of the selected trademark(s) and each of the three
parties will have [*] in which to either approve or reject the selection(s).
Vanda shall be responsible for the selection and registration of such
trademark(s) in all countries of the Territory at its own cost. In the event the
sublicense granted hereunder is terminated in a particular country, other than
pursuant to Section 10.3 or as a result of Vanda's termination of this
Sublicense Agreement for breach pursuant to Section 10.5, and Novartis exercises
the right to promote, market or sell the Product in such country then upon
Novartis' request (a) Vanda shall grant to Novartis or its designee(s) a
trademark license at a royalty to be negotiated in good faith (which royalty
shall not be less than [*] percent ([*]%) and no more than [*] percent ([*]%) on
[*]) at such time to use such trademark in connection with marketing the Product
in such country, subject to reasonable quality control by Vanda with respect to
the Product sold under this Section 2.5(a), or (b) Novartis or its designee(s)
shall select and register at Novartis' cost a trademark of its own in connection
with the marketing of the Product in such country, provided such Novartis
trademark is not in any way confusingly similar to the Vanda trademark. Novartis
shall use the trademark that

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 9 of 59
<PAGE>
that party acting alone has chosen as a trademark (rather than a Vanda
trademark) in promoting, marketing or selling the Product in any country that is
a member of a free trade union or other economic grouping (e.g., the European
Union, EEA, NAFTA, ASEAN and ANDEAN Pact countries) where Vanda is promoting,
marketing or selling the Product under a Vanda trademark.

2.6 If Vanda notifies Novartis in writing that Vanda (and/or its Affiliate(s))
is not willing or does not have the capability itself or cannot enter into a
Sublicense or other agreement (providing the necessary expertise and resources)
in country(ies) outside those covered by NAFTA and the European Union to:(a)
develop the Compound or Product (as the case may warrant), and (b) manufacture
the Compound and/or market the Product (as the case may warrant) at a
Competitive Industry Standard Level at the date of Product approval in such
country(ies), then Novartis shall have the right to terminate the sublicense
granted by this Sublicense Agreement but only with respect to such country(ies),
unless the parties agree in writing to extend such time frame.

2.7 If the Product is not launched in the United States or a Major Market
Country at a Competitive Industry Standard Level by Vanda, its Affiliate and/or
Sublicensee within [*] after the date of receiving the approvals necessary to
commercialise the Product in [*] or a Major Market Country Vanda and Novartis
shall review the progress of launch efforts, it being understood that the
parties, at the request of a party, may review the progress of launch efforts
prior to the end of [*] period, and Vanda shall keep Novartis and HMRI informed
on a regular basis of the status of its launch efforts after receiving the
approvals necessary to commercialize the Product in the United States or a Major
Market Country until such time that launch is achieved in the United States or a
Major Market Country. If launch in the United States or a Major Market Country
is not achieved within [*] after the date of receiving the approvals necessary
to commercialize the Product in such country(ies) (circumstances shall not
include events of force majeure as defined in Section 13), or in any event
within [*] after Product approval then the sublicense granted by this Sublicense
Agreement shall terminate, but only with respect to the particular country where
launch was not achieved within [*] time frame, as the case may be, unless the
parties agree in writing to extend such time frame (the parties shall discuss in
such event, factors including but not limited to the necessity to obtain
approval of Product for its target indication(s)).

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 10 of 59
<PAGE>
2.8 If an NDA or equivalent ex-US. regulatory approval in the European Union
(Marketing Authorization Application via the Centralized Procedure or marketing
approvals for the member countries of the European Union via the mutual
recognition procedure) for the Product not obtained within [*] of Vanda's or its
Affiliate's or Sub-licensee's filing of an NDA or such other equivalent ex-U.S.
filing, and such failure is solely due to circumstances within Vanda's
reasonable control, then the parties shall discuss the reasons and proposed
remedies (or such failure in good faith; provided, however, that if the parties
are unable to agree on. Any such remedies, Novartis shall have the right to
terminate the sublicense granted by this Sublicense Agreement, but only with
respect to the United States or the European Union where such approval was not
obtained, unless the parties agree in writing to extend such time frame. If,
however, [*] such failure is due to circumstances beyond the reasonable control
of Vanda (including without limitation delays on the part of the regulatory
agencies), the [*] period shall be extended to take into account such
circumstances, the duration of any such extension to be mutually agreed.

2.9 Subject to the provisions of Section 2.9(d), [*] with respect to any
country(ies) which cease to be included within the Territory, and in the event
that (i) Novartis or its Affiliate(s) or Sub-licensee(s) elects to commercialise
the Product or Compound in such country(ies) and (ii) Vanda, its Affiliate(s) or
Sublicensee(s) has an NDA filing in the United States or an equivalent filing in
the European Union, then in consideration for the use of any IND, NDA or other
governmental approval or associated developmental work held or owned by Vanda
related to the Compound or Product:
(a) At Novartis' request, and subject to Sections 6.3 and 11.5 hereof, Vanda
shall license or otherwise make available under applicable law the benefit of
such approvals or work to Novartis or an Affiliate or Third Party designated by
Novartis (which third party could be HMRI or Titan), who shall thereafter have
the rights to develop, register, manufacture, market and sell the Compound and
Product in such country(ies) utilizing such approvals or work, and Novartis (or
such Affiliate or Third Party) shall pay to Vanda a royalty [*]. Such royalty
shall not be greater than [*] percent ([*]%) on [*]

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 11 of 59
<PAGE>
Upon expiration of the Patent in such country, only the royalty paid to Vanda
for the use of the Vanda trademark under Section 2.5 shall be paid to Vanda for
so long as such trademark is utilized. If a trademark license has not been
granted to HMRI, Titan or Novartis in such country, no royalty shall be paid to
Vanda upon the expiration of the Patent.

(b) Novartis shall share [*] with Vanda any [*] received from a Third Party in
connection with the exercise of such option only. If Vanda has not paid to
Novartis the up front license fee and all of the milestone payments provided for
in Sections 3.1(a) through (c), then [*].

(c) Notwithstanding anything contained herein to the contrary, Novartis shall
not be required to pay to Vanda a royalty on sales of the Product that, when
added to the royalty payments for a license under the Vanda trademark payable
under Section 2.5, exceeds [*] ([*]%).

(d) If the circumstances leading up to the termination of the Sublicense
Agreement pursuant to Section 2.8 are due to any misrepresentations, omissions
(of information owned or controlled by Novartis or its Affiliates; as of the
date hereof) or falsifications with respect to such Know-How, information or
data or fraud by Novartis or its Affiliates, then subject to the following
sentence, Novartis shall [*]. In the case of misrepresentations, omissions (of
information owned or controlled by HMRI, Titan or their Affiliates as of the
date hereof) or falsifications with respect to such Know-How, information or
data or fraud only by HMRI, Titan or their Affiliates, and a termination of the
HMRI Agreement pursuant to Section 2.5 of the HMRI Agreement, Novartis shall be
[*].

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 12 of 59
<PAGE>
2.10 In the event that Vanda or a Sublicensee intends to seek a co-promotion or
co-marketing partner for the Product in the United States, Vanda shall notify
Novartis thereof in writing. Novartis shall then notify Titan thereof, and HMRI
shall have a right of first negotiation with Vanda or the Sublicensee on such a
collaboration. If HMRI exercises its right of first negotiation, then HMRI and
Vanda or the Sublicensee shall negotiate in good faith for a period of [*] from
the date of notification by Novartis to HMRI. If the negotiating parties are
unable to enter into a separate definitive written agreement regarding such
collaboration by the end of such [*] period, first Novartis and then Titan will
have the right to negotiate with Vanda in good faith for a [*]. In the event
that Vanda or its sublicensee is unable to enter into a separate definitive
written agreement regarding such collaboration by the end of such [*] period
with Novartis or Titan, Vanda or the Sublicensee shall be free to enter into a
collaboration with any Third Party subject to all other terms of this Sublicense
Agreement and shall have no further obligation to negotiate with HMRI. For the
purposes of this Section 2.10, the term "co-promotion or co-marketing partner"
will not include [*] that may be engaged by Vanda or a Sublicensee.

3. PAYMENTS AND ROYALTIES.

3.1 As consideration for the sublicenses granted to Vanda by Novartis under this
Sublicense Agreement, Vanda shall make the following payments to Novartis:

(a) An up front license fee of [*] shall be paid by Vanda to Novartis in cash
within [*] days of both parties' execution of this Sublicense Agreement.

(b) A first development milestone payment of [*] be payable by Vanda to Novartis
[*] upon [*] for the Product in the Field [*]. As used in this Section, [*]

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 13 of 59

<PAGE>
Such milestone payment shall be paid in cash by Vanda directly to Novartis
within [*] of the date of [*]. The [*] provided for herein shall, unless
otherwise expressly provided for herein, be [*].

(c) A second development milestone payment of [*] which shall be payable [*] by
Vanda to Novartis on [*].

(d) Vanda shall notify Novartis in writing [*] prior to Vanda's estimated
achievement of each milestone event described in Sections 3.1(b) and 3.1
(c)(i) above and Vanda shall make each such payment within [*] of the
achievement of the milestone event for which such payment is due.

3.2 (a) Unless Novartis instructs Vanda in writing otherwise, all cash payments
by Vanda to Novartis (including, without limitation, up front payments,
milestone payments, and royalties) shall be made by bank wire transfer as
follows:

Bank: [*]
Swift: [*]
Correspondent Bank for USD: [*]
USD Account Novartis AG, Basel/Switzerland: [*]
USD Account Novartis Pharma AG, Basel/Switzerland: [*]

(b) At least [*] days prior to the planned wire transfer to either of the above
accounts, Vanda shall notify Novartis of the amount and date the cash shall be
transferred.

(c) In the event of a late payment hereunder by Vanda to Novartis, Vanda shall
pay to Novartis [*]([*]%) on the outstanding balance until such balance,
including interest, is paid in full to Novartis. The acceptance of such late

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 14 of 59
<PAGE>
payment shall act as a waiver of any rights Novartis may have hereunder due to a
breach by Vanda relating solely to such payment being made late.

3.3 As consideration for the sublicense granted to Vanda in this Sublicense
Agreement, Vanda shall pay to Novartis, in those countries where, and for the
period, Patents claiming a priority date of May 19, 1989 and December 29, 1989
or Patents owned by Novartis AG in a particular country in the Territory for
which a patent had been granted validly claiming Iloperidone or the manufacture,
formulation or the use thereof for use in the Field:

(a) [*] per cent ([*]%) royalty on annual Net Sales of the Product of
Vanda, its Affiliates' and Sublicensees' annual Net Sales of the Product in the
Territory.

(b)Vanda shall also pay to Novartis the following milestone payments:

<Table>
<Caption>

Net Sales Milestone                                                  Milestone payment from Vanda to Novartis
<S>                                                                  <C>
(A) Achievement of [*]                                               [*]
(B) [*]                                                              [*]
(C) [*]                                                              [*]
</Table>

No [*] shall be payable by Vanda within one calendar year. In the event that a
[*] becomes due and payable [*]. Milestone (C) shall be payable at the earliest
on [*].

3.4 (a) In order to spread royalty payments hereunder over a sufficient period
of time, in each of those countries in the Territory where the Patents claiming
a priority date of May 19, 1989 and December 29, 1989 or Patents owned by
Novartis AG in a particular country for which a patent had been granted validly
claiming Iloperidone or the manufacture, formulation or use hereof for use in
the Field have expired, Vanda's obligations to pay royalties for use of Patents
in such country shall cease, and Vanda and/or any of its Sublicensees shall pay

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY
WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO
THE OMITTED PORTIONS.

                                 Page 15 of 59
<PAGE>
directly to HMRI a royalty for [*] percent ([*]%) on Vanda's, its Affiliates'
and any Sublicensees' annual Net Sales of the Product in each such country for a
period of ten (10) years after the expiration of the final remaining Patent
claiming a priority date of May 19, 1989 and December 29, 1989 or Patents owned
by Novartis AG in each such country. After the end of such ten (10) year
period, no further royalties arising from sales of the Product in such country
shall be due to HMRI and Vanda shall be entitled to continue to use [*] on a
fully-paid, irrevocable basis in accordance with Section 10.3.

(b) In the event that a Third Party's generic version of Iloperidone is actively
marketed in a process patent country (that is, any country in which the only
protection in relation to processes for the manufacture of Iloperidone has been
obtained and not protection for Iloperidone as a new chemical entity per se) in
the Territory where a Patent(s) has been granted validly claiming Iloperidone or
the manufacture, formulation or use thereof for use in the Field exists, then
subject to Sections 3.4( c) and (d) below, the royalty rate that Vanda shall pay
to Novartis on Vanda's or its Affiliate's or Sublicensees annual Net Sales of
the Product in that process patent country shall be [*] percent ([*]%) until
such Patent(s) expires, provided: (i) [*]; and (ii) [*]. Unless otherwise agreed
to by the parties, [*] until [*] or until [*].

(c) If it is demonstrated to the satisfaction of both Parties or the binding
unappealable judicial determination under Section 3.4(b)(ii) holds that
Patent(s) are not being infringed in such process patent country, the royalty
rate that Vanda shall pay to Novartis on Vanda's or its Affiliate's or
Sublicensee's annual Net Sales of Product in that process patent country shall
[*] percent ([*]%) until such Patent(s) expires.

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 16 of 59
<PAGE>
(d) If the binding, unappealable judicial determination under Section 3.4(b)(ii)
holds that Patent(s) are being infringed in such process patent country, [*]. If
as a result, the commercialization of Iloperidone by the Third Party in that
country is discontinued:

      (i) the royalty rate(s) that Vanda shall pay to Novartis on Vanda's or its
      Affiliate's or Sublicensee's annual Net Sales of the Product in that
      process patent country shall be, commencing on the later of: (A) the date
      such binding, unappealable judicial determination is rendered, and (B) the
      date (if any) specified in such determination that commercialization of
      such Third Party generic version of the Product is to be discontinued,
      those royalty rates provided for in Section 3.3 until such Patent(s)
      expires; and
      (ii) Vanda shall repay to Novartis, within thirty (30) days after the
      later of: (A) the date such binding, unappealable judicial determination
      was rendered, and (B) the date (if any) specified in such determination
      that commercialization of such Third Party generic version of the Product
      is to be discontinued, an amount equal to the difference between the
      royalties that Vanda would have paid to Novartis under Section 3.3, and
      the amount of royalties that Vanda actually paid to Novartis at the [*]
      percent ([*]%) rate, for the period commencing on the date the royalty
      rate for that process patent country was reduced to [*] percent ([*]%)
      pursuant to Section 3.4(b), and ending on the later of: (A) the date such
      binding, unappealable judicial determination was rendered, and (B) the
      date (if any) specified in such determination that commercialization of
      such Third Party generic version of the Product is to be discontinued.

(e) After a Patent(s) in any process patent country expires, Vanda and/or its
Sublicensee shall pay directly to Novartis royalties as provided for in Section
3.4(a).

3.5 As consideration for the sublicense granted to Vanda under this Sublicense
Agreement in those countries in the Territory for which (a) a Patent application
for the Compound or Product is pending or (b) no Patent application has been
filed or (c) Patents have been abandoned or been held invalid or unenforceable
by a decision of a court or tribunal of competent jurisdiction from which no
appeal is or can be taken (collectively, "Non-Patent Countries"), Vanda shall
pay to Novartis, on a country-by-country basis, a [*] percent

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 17 of 59
<PAGE>
([*]%) royalty for [*] on Vanda's, its Affiliates' and any Sublicensees' annual
Net Sales of the Product in the Non-Patent Countries for a period of five (5)
years from the date of the first commercial sale of the Product in each such
country by Vanda, its Affiliates or Sublicensees. After the end of such five (5)
year period, no further royalties arising from the sales of the Product in such
country shall be due. However, with respect to Section 3.5(a) or (b), if at any
time during or after such five (5) year period a Patent for Compound or Product
is issued in such country, subject to Section 3.4, Vanda shall pay to Novartis,
from the date the Patent was issued, the same royalties as provided for in
Sections 3.3(a) and (b) above. Upon expiration of Vanda's obligation to pay a
royalty under such Patent, notwithstanding Section 3.4, a [*] percent ([*]%)
royalty for [*], on Net Sales of the Product in such country, shall be paid by
Vanda and/or any of its Sublicensees directly to HMRI for a period of five (5)
years after which Vanda shall be entitled to continue to use the Know-How on a
fully-paid, irrevocable basis in accordance with Section 10.3.

4. COMPULSORY LICENSES AND THIRD PARTY LICENSES

4.1.(a) In the event that during the term of this Sublicense Agreement a
governmental agency in the Territory grants or compels HMRI and/or Titan and/or
Novartis to grant a license to any Third Party for the Compound or Product in a
country(ies), it is the intent of the parties that [*]. Therefore, in the event
that Novartis, Titan or HMRI is compelled to grant a license to a Third Party,
Novartis, Titan and HMRI will [*] consideration will be given to Novartis'
obligations to HMRI and Titan under Section 4.l(d) of the Titan Agreement.

(b) If a governmental authority in a country in the Territory imposes a maximum
royalty rate, such that lower royalty rates than would otherwise apply under
this Sublicense Agreement are mandated in such country, then the royalty rates
provided for herein shall be reduced to

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 18 of 59
<PAGE>
equal such lower rates for sales of the Product in such country for the period
such lower royalty rate is required by any governmental authority and shall
cease when Vanda's royalty payment obligations cease under this Sublicense
Agreement.

4.2 If, during the term of this Sublicense Agreement, HMRI and Vanda agree that
patent(s) of a Third Party exists in the Territory covering the manufacture, use
or sale of the Compound or Product, and if it should prove, in the reasonable
judgment of Vanda and HMRI, impractical or impossible for Vanda or its
Affiliates or Sublicensees to continue the activity or activities sublicensed
hereunder in the Field without obtaining a royalty-bearing license from such
Third Party under such patent(s) or if Vanda and HMRI otherwise agree it is
desirable for HMRI to acquire any Third Party patent or license in connection
with the development or manufacture of Compound or Product covered by Patents in
the Territory, then in either case the provisions of Section 8.8(c) shall apply.

4.3 If, after attempting in good faith to resolve the issue relating to
licensing Third Party patents in Section 4.2 between themselves, Vanda and HMRI
are unable to agree within ninety (90) days as to whether it is impracticable or
impossible for Vanda, its Affiliates or Sublicensees to continue the activity or
activities sublicensed hereunder without obtaining a royalty-bearing license
from a Third Party, the issue shall be submitted to a disinterested, competent
and experienced patent attorney reasonably acceptable to both Vanda and HMRI for
resolution. If Vanda and HMRI cannot agree on the selection of such patent
attorney, then each party shall select a patent attorney and the selected patent
attorneys shall select a mutually acceptable patent attorney who will determine
whether such Third Party rights materially inhibit Vanda's ability to
manufacture, distribute or sell the Compound or Product. The compensation to,
and expense of such patent attorney shall be borne [*].

5. DEVELOPMENT

5.1 Upon the signing of this Sublicense Agreement, Vanda shall have full legal
and financial responsibility for all costs that are incurred and all activities
that are undertaken after the

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 19 of 59
<PAGE>
signing of this Sublicense Agreement, which are related to development, safety
and required periodic reporting to the FDA and equivalent ex-U.S. regulatory
agencies, marketing, regulatory approvals, price registrations, and other
activities required by Vanda or its Sublicensee(s) (or their respective agents
or distributors) to obtain appropriate government approvals for, and to
commercialize, the Compound and Product in the Territory. Other than as
expressly provided for in Section 5.4, Vanda shall not assume, nor shall Vanda
be liable for, any costs or activities (whether scientific, financial or
otherwise) relating to the Compound or Product that were incurred or undertaken
prior to the signing of this Sublicense Agreement (including without limitation
any costs, expenses, damages, losses, fines, penalties or the like that may be
awarded or assessed after the signing of this Sublicense Agreement, but which
arise out of events and activities that occurred prior to the signing of this
Sublicense Agreement).

5.2 Provided that the Affiliates, Sublicensees and other Third Parties agree to
substantially the same terms of confidentiality in Section 6.4 hereof, Vanda may
appoint such Affiliates, Sublicensees(s) and other Third Parties to perform any
and all development activities necessary to obtain government approvals for the
Product in the Territory. The appointment of any Sublicensee shall require
HMRI's prior written consent, which consent shall not be unreasonably withheld.

5.3 Vanda shall, in a manner [*] exercise its Commercially Reasonable Efforts
and diligence in conducting clinical trials and commercializing the Product
alone or in collaboration with a Third Party, and in undertaking those
investigations and actions required to obtain appropriate governmental approvals
to manufacture the Compound and market the Product in the Territory. All such
activity shall be undertaken at Vanda's expense. Novartis shall arrange with
HMRI to provide assistance or consultation at Vanda's expense in support of the
development of the Compound or Product, but HMRI in its discretion may limit
such assistance and consultation.

5.4 The parties further agree that:

(a) Novartis will be informed by Vanda on a timely and regular basis of the
development, registration and commercialisation of the Compound and Product in
the Territory, and will

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 20 of 59
<PAGE>
have an opportunity to regularly meet with Vanda and provide input into the
development and registration process, and

(b) all of Novartis contractual obligations to Third Parties involved in the
development and registration process for the Compound and Product (including
Contract Research Organizations (CROs) existing as of the date of this
Sublicense Agreement, which CROs are identified in APPENDIX E), will be
considered by Vanda to the extent they are not inconsistent with Vanda's
Standard Operating Procedures.

(c) Vanda shall be solely responsible for the negotiation of contracts with any
CROs and other organisations it desires to work on development activities
relating to the Compound and/or Product and Vanda shall bear all legal and
financial responsibility under such contracts.

5.5 Any inventions or discoveries or improvements which arise from Vanda's, its
Affiliates' or Sublicensees work relating to the development and/or manufacture
of the Compound and/or Product shall be owned by Vanda, but shall be licensed to
HMRI, Titan and Novartis at their option on a worldwide, non-exclusive,
perpetual basis, at a license fee and/or royalty [*]. In the case of any
inventions or discoveries or improvements arising in areas outside of the
original field, which was defined in the HMRI Agreement and the Titan Agreement,
shall be owned by Vanda, but shall only be licensed to HMRI, at HMRI's option on
a worldwide, non-exclusive, perpetual basis, at a license fee and/or royalty
[*]. Notwithstanding anything to the contrary in this Sublicense Agreement, in
the event that this Sublicense Agreement between Novartis Pharma AG and Vanda
Pharmaceuticals, Inc. expires or terminates, in its entirety or with respect to
any country, (except as a result of material breach of the Agreement by
Novartis), any inventions or discoveries or improvements which arise from
Vanda's, its Affiliates' or Sublicensees' work relating to development and/or
manufacture of the Compound and/or Product (the "Vanda IP") shall be disclosed
to HMRI and be owned by and become the property of HMRI (or assignees or
successors, as the case may be), but shall be licensed to Titan under Section
2.1(a) of the HMRI-Agreement and subsequently to Novartis under the Titan
Agreement. Vanda shall promptly undertake any and all actions necessary to
effectuate such ownership in and assignment to HMRI. If the Vanda Sublicense
Agreement expires or terminates with

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 21 of 59
<PAGE>
respect to a particular country, then the requirements of this Section 5.5 and
Aventis' rights to the Vanda IP shall be limited to such country.

5.6 deleted.

5.7 In addition to that which is required under Section 5.4(a), Vanda shall
provide to Novartis regular written reports at least every [*] setting forth
significant developments and improvements, including the status and progress of
the development and/or registration activities, that affect the Compound or
Product.

5.8 Vanda, or its Sublicensees, shall promptly advise Novartis in writing upon
the submission and filing for government regulatory approval to manufacture and
market the Product, and upon the receipt of government regulatory approval to
market the Product, in each case in each country in the Territory, and shall
commence marketing the Product in such country in accordance with Section 5.3.

5.9 Subject to applicable laws and regulations, labeling on all Product sold by
or on behalf of Vanda pursuant to this Sublicense Agreement, and all
advertising, marketing and promotional materials used in connection therewith,
will identify Novartis as the licensor of the Product.

5.10 If at any time during the term hereof a product is developed by Vanda or
any of its Affiliates or Sublicensees, which product contains the Compound and
one or more other pharmaceutically active ingredients for use in the Field (a
"Combination Product"), Novartis shall [*], this Sublicense Agreement shall be
[*] by Novartis and Vanda to provide for such Combination Product.

6. EXCHANGE OF INFORMATION AND CONFIDENTIALITY.

6.1 Upon the signing of this Sublicense Agreement, Novartis shall deliver to
Vanda, all available Know-How, documents, information and data which is owned or
controlled by Novartis and its Affiliates, which may be reasonably expected to
assist Vanda in developing, registering, manufacturing and marketing the
Compound and Product in the Territory. After the execution of this Sublicense
Agreement, there shall be a [*] transition period

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 22 of 59
<PAGE>
during which Novartis shall provide, at its own cost, reasonable resources,
expertise, and documents to effectively transfer the Know-How and development
activity to Vanda. Banked DNA samples and or animal tissues treated with the
compound will only be made available to Vanda for further studies in accordance
with the protocols and informed consents set forth at the time of sample
acquisition provided however that no human tissue samples with identifiable
patient data will be transferred to Vanda. All raw data and individual clinical
and genetic data will be transferred to Vanda under a mutually agreed coding
schema, in order to protect patient confidentiality. All original identifiable
patient data will, however be provided to the FDA as part of the submission
package. If Vanda requires additional genotyping on existing samples, Novartis
will contract this work out, in accordance with the informed consents, on
Vanda's behalf and at Vanda's cost. If further DNA samples from past study
patients are desired, Vanda will revisit the sites and try to consent or
reconsent these patients for additional DNA sampling. Upon Novartis' receipt of
the up front license fee referred to in Section 3.1(a) hereof, Vanda and
Novartis each shall promptly provide written notification to the FDA that
Novartis assigns and that Vanda assumes sponsorship of the U,S. IND No. 36,827
(as specified in 21 CFR 314.72). Within [*] after the date of such written
notification, Novartis shall transfer the U.S. IND for the Compound or Product
to Vanda. Until such transfer is made, Vanda shall have the right to make
reference to such Compound or Product owned or controlled by Novartis or its
Affiliates. Furthermore, upon Novartis' receipt of the upfront license fee
referred to in Section 3.1(a), Novartis shall arrange for the transfer to Vanda
of Canadian IND Control No. 27740.

6.2 Vanda shall have Exclusive use, subject to the terms of this Sublicense
Agreement and in particular Section 2.3, of all Know-How, documents,
information, data and material for the development, registration, manufacture
and marketing of the Compound and the Product for use in the Field in the
Territory. Novartis and its respective Affiliates shall keep confidential all
Know-How, documents, information and data in their possession or received from
or generated by or on behalf of Vanda that is not already in the public domain
relating to the Compound and Product regarding the use in the Field with the
same level of care that Novartis and its respective Affiliates use for their own
confidential information. Upon Novartis' request during the term of this
Sublicense Agreement, Vanda shall deliver to Novartis a copy of all such
information and data in a form to be mutually agreed upon, within thirty (30)
days after Novartis' request, it being understood and agreed that any and all
such information and data will be made available by Novartis to Titan, upon
Titan's request.

6.3 Subject to the confidentiality obligations of this Article 6, Vanda shall
make available and HMRI, Titan and Novartis shall be able to freely use Know-How
and documents, information and data relating to the Compound and/or Product
disclosed or generated by Vanda, its Affiliates and Sublicensees and
applications for government approvals (United States or

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 23 of 59
<PAGE>
European Union or Japan), reports on the status and progress of the development
of the Compound or the Product and the like in any country(ies) deleted from the
Territory and to which this Sublicense Agreement has been terminated pursuant to
the terms hereof.

6.4 During [*] Vanda shall not reveal or disclose to a Third Party or use for
any purpose other than to perform its obligations herein any Confidential
Information (as defined below) without first obtaining the written consent of
Novartis, except as may be otherwise provided herein, or for securing essential
or desirable authorizations, privileges, licenses, registration or rights from
governmental agencies, or is required to be disclosed to a governmental agency
or is necessary to file or prosecute Patent applications concerning the Compound
or Product or to carry out any litigation concerning the Compound or Product
provided, however, that Vanda notifies Novartis in writing in a reasonably
sufficient time frame prior to making such disclosure that Vanda intends to make
such disclosures and the details thereof, and Vanda seeks confidential treatment
where available of such Confidential Information from such governmental
agencies. This confidentiality obligation shall not apply to such information
which is or becomes a matter or public knowledge through no fault of Novartis,
or is already in the possession of Novartis as evidenced by written records, or
is disclosed to Vanda by a Third Party having the right to do so, or is
subsequently and independently developed by employees of Novartis or its
Affiliates who had no knowledge of the Confidential Information. Vanda shall
take reasonable measures to assure that no unauthorised use or disclosure is
made by others to whom access to such information is granted. As used herein,
"Confidential Information" means, any confidential or proprietary information of
HMRI, Titan or Novartis or their Affiliates, including any present or future
formulas, research project, work in process, inventions, procedures,
development, scientific, engineering, manufacturing, marketing, business or
financial plan or records, products, sales, suppliers, customers, or investors,
whether such confidential or proprietary information is in oral, written,
graphic or electronic form (including all copies in whole or in part of any of
the foregoing) and which derives value from being known to the disclosure or
owner.

6.5 After transfer of the United States and Canadian INDs to Vanda under Section
6.1, Novartis and Vanda shall co-operate with respect to the exchange of adverse
event and safety information associated with Compound and Product, and such
information shall be coordinated by Vanda central clinical, safety and
epidemiology organisation. Details of the obligations of the parties with
respect to reporting such information to each other, and processing of this data
shall be covered in an addendum following execution of this Sublicense
Agreement.

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 24 of 59
<PAGE>
6.6 Nothing herein shall be construed as preventing Vanda from disclosing any
information received from Novartis to an Affiliate, Sublicensee, distributor,
contractor, agent, consultant, legal counselor other Third Party involved in the
development, manufacture, marketing, promotion or sale of the Compound or
Product, provided that such Affiliate or Sublicensee or other Third Party has
undertaken a similar obligation of confidentiality with respect to the
Confidential Information.

6.7 In the event that a court or other legal or administrative tribunal,
directly or through an appointed master, trustee or receiver, assumes partial or
complete control over the assets of Vanda based on the insolvency or bankruptcy
of Vanda, Vanda shall promptly notify the court or other tribunal (i) that
Confidential Information received from Novartis remains the property of HMRI,
Titan or Novartis, or their respective Affiliates, as the case may be, and (ii)
of the confidentiality obligations under this Sublicense Agreement. In addition,
Vanda shall, to the extent permitted by law, take all steps reasonably necessary
or desirable to maintain the confidentiality of the Confidential Information of
HMRI, Titan or Novartis, as the case may be, and to ensure that the court, other
tribunal or appointee maintains such information in confidence in accordance
with the terms of this Sublicense Agreement.

6.8 No public announcement or other disclosure to a Third Party concerning the
existence of or terms of this Sublicense Agreement shall be made, either
directly or indirectly by either party to this Sublicense Agreement, except as
may be legally required, without first obtaining the approval of the other
party, which approval shall not be unreasonably withheld, and shall be given
within a reasonable time. The party desiring to make any such public
announcement or other disclosure shall provide the other party with a written
copy of the proposed announcement or disclosure in sufficient time prior to the
proposed public release, to allow such other party to comment upon the nature,
content and timing of such announcement or disclosure, prior to the proposed
public release. Notwithstanding the foregoing, Vanda shall be permitted to refer
to this Sublicense Agreement in presentation to prospective investors.

6.9 Neither party shall submit for written or oral publication any manuscript,
abstract or the like which includes Know -How, data or other information
generated and/or provided by Novartis or Vanda pursuant to this Sublicense
Agreement without first obtaining the prior written consent of the party
generating or providing such information, which consent shall not be
unreasonably withheld. The contribution of each party shall be noted in all
publications or presentations by acknowledgment or co-authorship, whichever is
appropriate.

7. NOVARTIS SUPPLY OF COMPOUND AND PRODUCT TO VANDA.

7.1 Novartis shall supply Compound and Product to Vanda under the following
conditions:

                                  Page 25 of 59
<PAGE>
(a) Within [*] after the Effective Date of this Sublicense Agreement as agreed
to by the parties in good faith, Novartis will, [*], arrange for the transfer to
Vanda, to a single site to be designated by Vanda, all quantities of milled
Compound available to it as of the Effective Date of this Sublicense Agreement.

(b) Title to, and risk of loss with respect to, all Compound and the Product
supplied by Novartis to Vanda under this Section 7.1 shall pass to Vanda upon
the receipt of such Compound and Product by Vanda or its designee at its point
of delivery. Novartis shall not be liable for any loss of such Compound and/or
Product except where such loss is the result of Novartis negligence or willful
misconduct.

(c) Novartis shall provide to Vanda the most recent certificate of analysis for
any shipment of Compound or Product.

(d) Novartis makes no representation or warranty that Compound and Product
supplied by it to Vanda for clinical trials will conform to the IND
specifications therefore as well as all laws and regulatory requirements,
including current Good Manufacturing Practices applicable to the Compound and
Product when used in clinical trials in accordance with the IND.

7.2 Novartis shall provide information and assistance to Vanda with respect to
the Compound and Product as follows:

(a) Within [*] after the full execution and delivery of this Sublicense
Agreement, Novartis shall deliver to Vanda any and all Know-How, documentation,
data and other information owned or controlled by Novartis and its Affiliates,
that Vanda may reasonably require for the manufacture of the Compound and
Product. Such information shall include without limitation the specifications
for the Compound and Product and methods of analysis for testing the Compound
and Product, as currently described within the IND regulatory documentation,
including Chemistry-Manufacturing/Controls(CMC) information amendments and the
technology transfer file.

(b) Novartis shall make reasonable commercial efforts to arrange for HMRI to
provide to Vanda or its designated Third Party assistance for the transfer of
manufacturing technology, through documentation, consultation and face-to-face
meetings, to enable Vanda or such Third Party to proceed with development of
commercial-scale manufacturing. If requested by Vanda or such Third Party,
Novartis shall visit the designated commercial manufacturing facility, with the
limitation of [*] visits, not to exceed a total of [*],

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 26 of 59
<PAGE>
for which Vanda shall bear all the costs of reasonable travel and other
out-of-pocket expenses.

7.3 Novartis represents and warrants that the specifications for the Compound
and Product are consistent with those set out in the INDs sponsored by Novartis.

7.4 Upon expiration or termination of this agreement, Vanda shall return to
Novartis, all unused Compound or Product supplied by Novartis hereunder.

8. PATENT PROSECUTION; MAINTENANCE AND EXTENSION; INFRINGEMENT

8.1 [*] shall be responsible for the filing, prosecution (including oppositions)
and maintenance of the Patents excluding Novartis Patents (hereinafter
"HMRI-Patents") [*]. For so long as the license grants set forth in Article 2
remain in effect, [*] agrees to file and prosecute and maintain the HMRI-Patents
in the Territory, provided that the foregoing is subject to [*] reasonable
business judgment. [*] shall keep [*] informed, [*], of important issues
relating to the preparation, filing, prosecution and maintenance of such
HMRI-Patent applications and HMRI-Patents. [*], shall have the right to
comment on [*] preparation, filing, prosecution and maintenance of HMRI-Patent
applications and HMRI-Patents, and [*] shall give clue consideration to Vanda's
comments, but HMRI shall make all decisions regarding the same.

8.2 If [*] elects not to seek patent protection in countries listed in APPENDIX
F or to maintain patent protection on HMRI-Patents listed in APPENDIX A in any
country in the Territory to the extent that HMRI-Patents claim the Compound or
the Product (or formulations, use or manufacture thereof), [*] shall have the
right, at its option [*], to file, prosecute (including oppositions) and
maintain any such HMRI-Patent applications and HMRI-Patents in HMRI's name, and
any HMRI-Patent issued therefrom shall be owned by HMRI. [*] shall advise [*] of
[*] decision) not to seek or maintain patent protection in a reasonably timely
manner. In the event that a HMRI-Patent is issued covering the Compound or
Product in any country in the Territory under the conditions of this Section
8.2, [*] shall pay directly to [*] a [*] ([*]%) royalty on Net Sales of Product
in such country, for a period of [*] years from the date of such patent issuance
in such country, in recognition of [*] Know-How and manufacturing rights and the
right to make and sell the Compound or Product in such

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 27 of 59
<PAGE>
country. Legal fees and expenses, [*], incurred [*] shall be [*].

8.3 [*] shall be responsible for the filing, prosecution (including oppositions)
and maintenance of the Patents owned by Novartis (hereinafter
"Novartis-Patents") [*]. [*] agrees to file and prosecute and maintain the
Novartis-Patents in the Territory, provided that the foregoing is subject to [*]
reasonable business judgment. [*], shall have the right to comment on [*]
preparation, filing, prosecution and maintenance of Novartis-Patent applications
and Novartis-Patents, and [*] shall give due consideration to Novartis'
comments. If [*] elects not to maintain patent protection on Novartis-Patents in
any country, [*] shall have the right, at its option, to file, prosecute and
maintain any such Novartis-Patent. [*] shall have the right but not the
obligation to enforce Novartis-Patents against Third Parties [*], and if [*]
does not act, [*] may in its sole discretion take such enforcement action as [*]
deems necessary.

8.4 Each of HMRI, Titan, Novartis and Vanda shall make available to the other,
its employees, agents, subcontractors or consultants (including its authorized
attorneys) to the extent reasonably necessary or appropriate to enable the
appropriate party to file, prosecute and maintain patent applications and
resulting patents subject to this Sublicense Agreement to the extent that
Patents claim the Compound or Product (or formulations, use or manufacture
thereof). Where appropriate, each of HMRI, Titan, Novartis and Vanda shall sign
or cause to have signed all documents relating to said patent applications or
patents [*].

8.5 Novartis shall obtain all assignments or licenses, as applicable from the
patent holder of the Patents, to the same extent as Novartis is entitled to
receive such assignments or licenses from HMRI and Titan under the HMRI
Agreement as applicable, to provide Vanda with the same degree of exclusivity in
the Territory under the Patents as Novartis is granted by HMRI and Titan under
the Titan Agreement.

8.6 Promptly after it is notified by HMRI and Titan, Novartis shall notify Vanda
in writing of (a) the issuance of each HMRI-Patent, giving the date of issue and
patent number for each patent, and (b) each notice pertaining to any
HMRI-Patent which HMRI receives as patent owner pursuant to the Drug Price
Competition and Patent Term Restoration Act of 1984, or other similar laws now
or hereafter in effect which extend the Patent life, or pursuant to comparable
laws or regulations in other countries in the Territory. [*], HMRI,
Titan, Novartis and Vanda shall co-operate with each other in applying for
patent term extensions (including Supplementary Protection Certificates in
European Union member states) where applicable in any country of the Territory.
HMRI shall have full

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 28 of 59
<PAGE>
responsibility and authority in the decisions regarding filing for the foregoing
HMRI-Patent extensions [*] although Vanda, through Novartis, shall be consulted
and its opinions given due consideration in such decision-making process. If
HMRI elects not to pursue extension of any HMRI-Patents, Vanda shall have the
right (but not the obligation) to apply for such extension in HMRI's name [*],
and HMRI shall reasonably co-operate in the filing and procurement thereof.

8.7 Except as otherwise expressly provided in this Sublicense Agreement, under
no circumstances shall a party hereto, as a result of this Sublicense Agreement,
obtain any ownership interest in or other right to any technology, Know-How,
Patents, pending Patent applications, products, or biological material of the
other party, Titan or HMRI, including items owned, controlled, discovered,
invented or developed by the other party, Titan or HMRI, or transferred by the
other party, Titan or HMRI to that party, at anytime pursuant to this
Sublicense Agreement which is not a direct result of the study, Know-How and
experimentation of the Compound and Product.

8.8 Each of Vanda, Novartis, Titan and HMRI shall promptly, but in any event no
later than [*] after receipt of notice of such action, notify the other in
writing of any Patent nullity actions, any declaratory judgment actions or any
alleged or threatened infringement of Patents or misappropriation of
intellectual property comprising Patents, or if Vanda, HMRI, Titan or Novartis,
or any of their respective Affiliates or Sublicensees, shall be individually
named as a defendant in a legal proceeding by a Third Party alleging
infringement of a patent or other intellectual property right of such Third
Party as a result of the manufacture, production, use, development, marketing,
selling or distribution of the Compound or Product, or of any information or
notification regarding the Patents.

8.9 [*] shall have the first right to respond to, defend or prosecute any
actions, challenges, infringements, misappropriations or proceedings by a Third
Party alleging infringement described in Section 8.8. In the event [*] elects to
do so, [*] will co-operate with [*] and its legal counsel, join in such suits as
may be brought by [*], and be available at [*] reasonable request to be an
expert witness or otherwise to assist in such proceedings and at [*] expense.
[*] will co-operate with [*] and its legal counsel and keep [*] and its counsel
reasonably informed at all times as to the status of [*] response or defense.

8.10 In the event that [*] elects to respond to, defend or prosecute any
actions, challenges, infringements, misappropriations or proceedings by a Third
Party claiming infringement described in Section 8.8 hereof, then: (a) legal
fees and other costs and expenses of [*] associated with such response or
defense shall be paid by [*]; (b) legal fees and other

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 29 of 59
<PAGE>
costs and expenses associated with such response or defense incurred by [*],
shall be paid by [*]; (c) the costs of acquiring Third Party patents or licenses
and any settlement, court award, judgment or other damages shall be paid by [*]
to such Third Parties [*]; provided, however, [*] shall not be obligated to
pay for any patents or licenses for uses of the Compound or Products not
disclosed in the Patents as of the date of the execution of the HMRI Agreement;
and (d) any amounts recovered from Third Parties in connection with such
response or defense shall be applied [*].

8.11 In the event that [*] respond to, defend or prosecute any actions,
challenges, infringements, misappropriations or proceedings by a Third Party
alleging infringement described in Section 8.8 hereof or [*] abandons any such
action, [*] shall notify [*] promptly after receiving notification from [*] of
such actions, challenges, infringements, misappropriations, proceeding or [*]
decision to abandon any such action. In such event, [*] shall have the option to
respond, defend or prosecute such action [*], provided that [*] shall co-operate
with and provide assistance to [*]. All amounts recovered from any Third Party
shall be applied [*].

8.12 In the event that [*] and [*] mutually agree that it is desirable for
[*] to acquire any Third Party patent or license in connection with the
development or manufacture of the Compound or Product covered by the
HMRI-Patents in the Territory then [*].

8.13 [*] recognises that [*] has reserved certain rights in [*] and that there
may be a legitimate dispute between the parties whether a legal action should be
brought against a Third Party which could affect [*] reserved rights [*] and [*]
rights [*]. In the event that there is a dispute between [*] and [*]
regarding [*] and therefore whether a legal action should be initiated, [*] and
[*] shall submit the issue to [*]. If [*] and [*] cannot agree on [*], then [*]
and [*] shall each [*]

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 30 of 59
<PAGE>
[*] That [*] and then [*] and [*] may decide [*] as described by this Article 8.
The compensation to, and expenses of, such [*].

9. STATEMENTS AND REMITTANCES.

9.1 Vanda shall keep, and require its Affiliates and Sublicensees to keep
complete and accurate records of all Net Sales of the Product under the
sublicenses granted herein. HMRI and Novartis shall have the right, at their
expense, through a certified public accountant or like independent person
reasonably acceptable to Vanda, and following reasonable notice, to examine such
records under conditions of confidentiality during regular business hours during
the period of time during which royalties are due and payable hereunder and for
[*] thereafter; provided, however, that such examination shall not take place
more often than [*] and shall not cover such records for more than the preceding
[*]; and provided further, that such accountant shall report to Novartis only as
to the accuracy of the Net Sales computation and royalty statements and
payments. It is agreed that if this Sublicense Agreement is terminated with
respect to a particular country(ies), then Novartis' examination rights shall
continue with respect to sales of the Product in such country(ies) only for a
period of [*] after the termination of sublicense rights in that country. Copies
of all such accountant's reports shall be supplied to Vanda.

9.2 Within [*] after the close of each [*], Vanda shall deliver to Novartis a
true accounting of all Product sold by Vanda, its Affiliates and Sublicensees
during such [*] and shall at the same time pay all earned royalties due. Such
accounting shall show Net Sales of Product on a country-by-country and
product-by-product basis and such other particulars as are reasonably necessary
for accounting of the royalties payable hereunder.

9.3 Any tax paid or required to be withheld by Vanda on account of royalties
payable by Vanda under this Sublicense Agreement shall be indicated on the
accounting described in Section 9.2 hereof and deducted from the amount of
royalties otherwise due. Vanda shall secure and send to Novartis or HMRI, as the
case may be, proof of any such taxes withheld and paid by Vanda. Any [*] by
Vanda or a Sublicensee shall be for the account of and paid by Vanda.

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 31 of 59
<PAGE>
9.4 Unless otherwise indicated herein, and subject to foreign exchange
regulations then prevailing, to the extent free conversion from local currency
to United States dollars is permitted, all payments and royalties payable under
this Sublicense Agreement shall be paid in cash in U.S. dollars by wire
transfer in accordance with Section 3.2 hereof. If governmental regulations
prevent remittances from a foreign country with respect to sales made in that
country, the obligation of Vanda to pay royalties on sales in that country shall
be suspended until such remittances are possible, but such royalties shall
accrue as accounts payable by Vanda to Novartis or HMRI, as the case may be.
Novartis or HMRI, as the case may be, shall have the right, upon giving written
notice to Vanda, to receive payment in that country in local currency.

9.5 Royalty payments and Net Sales shall be calculated on the basis of Vanda's
quarterly standard account of internal sales which represents the conversion of
all local currency sales for a calendar quarter into Swiss francs at the average
exchange rate: (as routinely derived via Vanda's standard methodology) for such
calendar quarter in which the sales are recorded. The exchange rate between the
Swiss franc and the U.S. dollar for the quarterly royalty payments to Novartis
or HMRI (as the case may be) shall be the exchange rates published in the
Foreign Exchange column of The Wall Street Journal, New York edition, or other
qualified source mutually acceptable to the parties on the last business day of
the calendar quarter for which the royalties are being paid. Notwithstanding the
foregoing, if there is a difference between any amount that Vanda pays to
Novartis or HMRI (as the case may be) under Sections 3.3, 3.4 or 3.5, and the
amount that Novartis is required to pay to Titan under the Titan Agreement
(which difference arises as a result of using the method for calculating
royalties that are due and payable under this Section 9.5, and the method for
calculating such royalties under Section 9.5 of the Titan Agreement), the
shortfall or excess (as the case may be) in royalty payments made by Vanda under
this Section 9.5 shall be paid by Vanda to HMRI or Novartis (as the case may be)
in the case of a shortfall, and by Novartis to Vanda in the case of an excess
payment by Vanda to Novartis under Section 3.3 or 3.5.

10. TERM AND TERMINATION

10.1 (a) Vanda will have the right to terminate the sublicense for the Territory
or on a country-by-country basis for [*] associated with the Product as
reasonably determined by Vanda. For this purpose "[*]" are ones which [*].

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 32 of 59
<PAGE>
(b) In the event of termination in the entire Territory by Vanda pursuant to
this Section 10.1, Vanda shall, within [*] of such termination,
return to Novartis any and all information and data (including new information
and data) relating to the Compound and Product, whether generated by or on
behalf of Titan, Novartis, HMRI or Vanda, and make no further use
thereof. Additionally, in such event, this Sublicense Agreement shall terminate
in its entirety and the sublicense granted hereunder shall revert back to
Novartis. Novartis shall retain all up front license fees and milestone payments
it had received up to the date of termination if, and only if, termination was
not due to any fraud, misrepresentations, omissions or falsifications of
information with respect to such Know-How, information or data owned or
controlled by HMRI, Titan, Novartis or their Affiliates as of the date hereof in
which case, to the extent that Novartis has for its own part perpetrated a
fraud, misrepresentation, omission or falsification of information with respect
to such Know-How, information or data owned or controlled by it, Novartis shall
repay to Vanda, within ninety-five (95) days of such termination, that portion
of the up front license fee and milestone payments Novartis had received from
Vanda up to the date of such termination. In no event shall Novartis be liable
to Vanda for any misrepresentation, omission or falsification of information
owned or controlled by HMRI or Titan or their Affiliates.

(c) Novartis may terminate this Sublicense Agreement by giving Vanda three
months prior written notice in the event that the time period elapsing between
patient dosing in clinical trials is greater than [*] or more than [*] elapses
between the grant of first marketing authorization in the United States or a
Major Market Country and the commercial launch of the Product in that country.

10.2 In the event the development of the Compound and Product is terminated
altogether by Vanda on or before January 1, 2006, for reasons other than those
described in Section 10.1, then this Sublicense Agreement shall terminate in its
entirety and the sublicense granted hereunder shall revert back to Novartis.
Novartis shall retain all up front license fees it had received up to the date
of termination and Vanda shall also pay a [*] penalty payment to Novartis if,
and only if, termination was not due to any fraud, misrepresentations, omissions
or falsifications (of information owned or controlled by HMRI, Titan, Novartis
or their Affiliates with respect to Know-How, information or data).

10.3 Unless otherwise terminated, this Sublicense Agreement shall expire on a
country-by-country basis upon the expiration of Vanda's obligation to pay
royalties under this Sublicense Agreement in each such country. Expiration of
this Sublicense Agreement under this provision shall not preclude Vanda, its
Affiliates and Sublicensees from continuing directly

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 33 of 59
<PAGE>
or indirectly to manufacture the Compound and market and sell Product and to use
Know-How without further royalty payments.

10.4 In the event there is a change in the control of Vanda, Vanda shall give
Novartis [*] and that the development and commercialisation of COMPOUND and
PRODUCT will continue per the terms of this Sublicense Agreement.

10.5 (a) If either party materially defaults in its performance of this
Sublicense Agreement and if such default is not corrected or if the party in
default is not exercising reasonably diligent efforts to cure such default
within [*] after receiving written notice from the other party with respect to
such default, or if such default is not correctable within [*] then such other
party shall have the right to terminate this Sublicense Agreement at the end of
such period in its entirety by giving written notice to the party in default. In
the event Vanda materially defaults in its performance under this Sublicense
Agreement with respect to a particular country, then, subject to Section 11.4
hereof, Novartis' right to terminate shall be limited to termination of the
sublicense granted hereunder in such country only.

(b) If Novartis materially defaults in its performance of the Sublicense
Agreement, then Vanda shall have the right but not the obligation to correct
or cure such default in the place of Novartis [*] provided for in Section 10.5
of the Titan Agreement without prejudice to any other rights Vanda may have
under this Sublicense Agreement (including the right to recover amounts paid to
Novartis), provided that (i) Vanda notifies Novartis in writing of Vanda's
election to do so, and (ii) Vanda's correction or cure of such default does not
increase Novartis' liability under the Sublicense Agreement.

(c) It is agreed that a material default by Novartis under the Titan Agreement
shall be a material default by Novartis under this Sublicense Agreement.

10.6 Subject to applicable bankruptcy laws, either party may terminate this
Sublicense Agreement if, at any time, the other party shall file in any court
pursuant to any statute of the United States or of any individual state or
foreign country, a voluntary petition in bankruptcy or insolvency or for
reorganisation in bankruptcy or for an arrangement or the appointment of a
receiver or trustee of the party or of its assets, or if the other party shall
be served with an involuntary petition against it, filed in any insolvency
proceeding, and such petition shall not be dismissed within ninety (90) days
after the filing thereof, or if the other party shall propose or be a party to
any dissolution, or if the other party shall make an assignment for the benefit
of creditors.

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 34 of 59
<PAGE>
(a) Without limitation, Vanda's rights under this Sublicense Agreement shall
include those rights afforded by 11 U.S.C. Section 365(n) of the United States
Bankruptcy Code and any successor thereto (the "Code"). If the bankruptcy
trustee of Novartis as a debtor or debtor-in-possession rejects this Sublicense
Agreement under 11 U.S.C. Section 365(n) of the Code, Vanda may elect to retain
its rights sublicensed from Novartis hereunder (and any other supplementary
agreements hereto) for the duration of this Sublicense Agreement and avail
itself of all rights and remedies to the full extent contemplated by this
Sublicense Agreement and 11 U.S.C. Section 365(n) of the Code, and any other
relevant sections of the Code and other relevant non-bankruptcy law.

11. RIGHTS AND DUTIES UPON TERMINATION.

11.1 Upon termination of this Sublicense Agreement (other than for Novartis'
breach), Novartis shall have the right to retain any sums already paid by Vanda
hereunder, and Vanda shall pay all sums accrued hereunder which are then due
except as otherwise defined in this Sublicense Agreement.

11.2 Upon early termination of this Sublicense Agreement in its entirety or with
respect to any country, under Sections 10.1 or 11.6 or due to a breach hereof by
Vanda, Vanda shall notify Novartis of the amount of Product that Vanda, its
Affiliates and Sublicensees then have on hand for sale in each country, the sale
of which would, but for the termination, be subject to royalty, and Vanda, its
Affiliates and Sublicensees shall thereupon be permitted to sell that amount of
Product, provided that Vanda shall pay the royalty thereon to Novartis, or HMRI,
as the case may be, at the time provided for.

11.3 Expiration or termination of this Sublicense Agreement or termination on a
country-by-country basis shall terminate all outstanding obligations and
liabilities between the parties arising from this Sublicense Agreement except
those described in Sections 6.2 (with sole respect to Novartis confidentiality)
6.3, 6.4, 6.5, 6.6, 6.8, 9.1, 9.2, 10.1, 10.2, 10.3, 11.1, 11.2, 11.4, 11.5,
11.6, 12.5, 12.6, 12.7, 14.1 and 14.2, which sections shall survive such
termination. In addition, any other provision required to interpret and enforce
the parties' rights and obligations under this Sublicense Agreement shall also
survive, but only to the extent required for the full observation and
performance of the surviving obligations under this Sublicense Agreement.

11.4 Except as otherwise specifically provided for herein, termination, in whole
or in part, of the Sublicense Agreement in accordance with the provisions hereof
shall not limit remedies to the parties which may be otherwise available in law
or equity, including consequential,

                                 Page 35 of 59
<PAGE>
incidental or indirect damages (such as loss of sales, profits, or goodwill)
arising out of a party's performance or nonperformance under this Sublicense
Agreement.

11.5 Subject to Section 11.2 and other express provisions hereof, upon early
termination of this Sublicense Agreement in its entirety due to breach hereof by
Vanda or pursuant to Sections 10.1, 10.2 or 11.6, Vanda's rights in the
Compound and Product shall cease, Vanda, its Affiliates and Sublicensees shall
cease manufacture, development, marketing and sale of the Compound and Product
in the Territory, and all originals and copies of Know-How, data, results and
other information collected and/or generated by Vanda, its Affiliates and
Sublicensees relating to the Compound or Product prior to termination shall be
delivered to Novartis within [*] thereafter, except for one copy thereof which
may be retained in Vanda's legal or other appropriately restricted files solely
for the purpose of establishing the extent of its obligations hereunder. Any IND
or other regulatory filing effected prior to termination shall be assigned by
Vanda to Novartis (or its designee(s), which designee may be HMRI or Titan),
[*], if not already assigned to Novartis. Vanda shall provide to Novartis,
within [*] of Novartis' request, copies of all regulatory correspondence,
including, but not limited to, IND Information Amendments, IND Reports, IND
Safety Reports, NDA submission, NDA Postmarketing Reports, and reports of
written/phone contacts to and from regulatory agencies, as well as the safety
database for the Product.

11.6 If (a) Vanda is precluded from selling the Product in a particular country
in the Territory by virtue of infringement of Third Party patent rights, or (b)
there is a holding of invalidity or unenforceability of any Patent, from which
no further appeal can be taken, that materially affects Vanda's ability to
commercialise the Product in a particular country in the Territory, Vanda shall
have the right but not the obligation to terminate this Sublicense Agreement in
such country. At Vanda's option, this Sublicense Agreement may be terminated in
its entirety if the events described in subsection (a) or (b) of this Section
11.6 occur in either the United States or two of the Major Market Countries.
Within [*] of any such termination, subject to the following sentence, Novartis
shall repay to Vanda if the Sublicense Agreement has been terminated in its
entirety, that portion of the up front license fee and milestone payments it has
received from Vanda up to the date of termination. In the event that the
Sublicense Agreement is terminated pursuant to Section 11.6 of the Sublicense
Agreement, Novartis shall be obligated to make the foregoing repayments to
Vanda, but only to the extent that it has been repaid its own up-front license
fee and milestone payments due to Novartis under Section 11.6 of the Titan
Agreement. If this Sublicense Agreement has been terminated only with respect to
certain country(ies), the parties shall negotiate in good faith a smaller
portion of the upfront license fee and milestone payments Novartis has received
from Vanda up to such date which shall be repaid to Vanda; provided, however, if

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 36 of 59
<PAGE>
the Titan Agreement has been terminated only with respect to such certain
countries under Section 11.6 of the Titan Agreement, Novartis shall be
obligated to make such repayments to Vanda but only to the extent Novartis has
been repaid the corresponding portion of the up front license fee and milestone
payments owed to it pursuant to Section 11.6 of the Titan Agreement. If the
parties are unable to agree on such smaller portions within ninety (90) days,
the issue shall be submitted for determination by arbitration in accordance with
Section 14.2.
12. WARRANTIES INDEMNIFICATIONS AND REPRESENTATIONS

12.1 Novartis represents and warrants that to the best of its knowledge at the
date of this Sublicense Agreement:
(a) all currently issued or pending patents and patent applications owned or
controlled by HMRI or its Affiliates or its Sublicensees claiming the Compound
or Product, are listed in Appendix A;
(b) HMRI or its Affiliates or its Sublicensees own or control the entire right,
title and interest in Patents and Know-How. If Novartis becomes aware of any
patents or patent applications owned or controlled by HMRI or its Affiliates or
Sublicensees claiming the Compound or Product or manufacture, formulation or
use thereof, not listed in Appendix A and is within the rights granted to Vanda
in this Sublicense Agreement, such patents and patent applications shall be
added to Appendix A at no cost to Vanda. Novartis further represents and
warrants that to the best of its knowledge as of the date of this Sublicense
Agreement;
(c) the Titan Agreement is in full force and effect and neither HMRI
nor Titan nor Novartis is in default of any of their obligations thereunder;
(d) subject to obtaining HMRI's and Titan's prior written consent, each of which
has been obtained, Novartis has the legal power, right and authority to enter
into this Sublicense Agreement; and
(e) Novartis has not previously assigned, transferred, conveyed or otherwise
encumbered its right, title and interest in the Patents or Know-How.

Vanda represents and warrants that it has the legal power, right and authority
to enter into this Sublicense Agreement.

12.2 Nothing in this Sublicense Agreement shall be construed as a warranty that
the Patents are valid or enforceable or that their exercise does not infringe
any patent rights of Third Parties. Novartis hereby represents and warrants that
it has no present knowledge (except as disclosed to Vanda or as available to
Vanda from public information) that (i) the Patents are invalid or
unenforceable, (ii) the exercise of Patents infringes any patent rights of Third
Parties, and (iii) Third Party licenses are necessary for the development,
manufacture or commercialisation of the Compound or Product. [*]

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 37 of 59
<PAGE>
of any Patent, from which no further appeal is or can be taken, shall not affect
any obligation already accrued hereunder, but shall only eliminate future
royalties otherwise due under such Patent from the date such holding becomes
final.

12.3 Each party represents and warrants to the other that it is not currently
debarred, suspended or otherwise excluded by any U.S. Government agencies from
receiving federal contracts.

12.4 Vanda represents and warrants that during the term of this Sublicense
Agreement, neither it, an Affiliate or a Sublicensee shall license, develop,
have developed, manufacture, have manufactured, sell or have sold any of the
following compounds or products classified as an atypical antipsychotic: [*].

In the event that Vanda or a Sublicensee undertakes any of the foregoing actions
within the EEA, then Novartis may not terminate this Sublicense Agreement or
seek damages or equitable remedies for such actions, but may at its option by
notice to Vanda (i) terminate the Exclusive nature of the licenses granted
pursuant to Article 2 hereof in the EEA, so that all use of Patents and Know-How
in the EEA will thereafter be on a non-exclusive basis at a reduced royalty rate
to be negotiated at time of change in exclusivity; (ii) cease providing
improvements to Vanda pursuant to Section 2.3; and/or (iii) require Vanda to
prove to Novartis' reasonable satisfaction that the Know-How is not being used
for such activities. Notwithstanding the foregoing, Novartis and Vanda agree
that in the event Vanda acquires rights to one or more of the [*] compounds or
products listed in the first paragraph of this Section 12.4 (the "Acquired
Compounds or Products") as part of a corporate transaction Novartis shall use
its good faith efforts to cause HMRI and Titan to waive any rights that it may
have against Vanda or Novartis under this Section 12.4 and Section 12.4 of the
Titan Agreement. To assist Novartis in obtaining such waiver from HMRI, Vanda
will provide Novartis with arguments supporting how Vanda intends to prevent the
Products from being negatively impacted by the Acquired Compounds or Products.
In the event that HMRI or Titan will not waive such rights and Vanda does not
agree to divest the Acquired Compounds or Products or, alternatively, sublicense
the Product to a mutually acceptable Third Party (which third party must also be
acceptable to HMRI and Titan), Novartis agrees that its sole and exclusive
remedy against Vanda shall be to terminate the Exclusive nature of the
Sublicense Agreement in the EEA as provided for in this Section 12.4, and to
terminate this Sublicense Agreement elsewhere in the Territory.

12.5 Vanda shall indemnify, defend and hold Novartis, HMRI, Titan and their
respective Affiliates harmless from and against any and all liabilities, claims,
demands, damages, costs,

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 38 of 59
<PAGE>
expenses, fines, penalties or money judgments including without limitation court
costs and reasonable attorney's fees (hereinafter referred to as "Liabilities"),
during the term of this Sublicense Agreement and after its expiration or
termination, incurred by or rendered against Novartis, Titan, HMRI and their
respective Affiliates which arise out of [*], except to the extent that such
Liabilities are directly attributable to the breach of this Sublicense Agreement
by Novartis or breach of the Titan Agreement by HMRI or Titan (including without
limitation any breach of Novartis' representations or warranties under this
Sublicense Agreement or any breach of HMRI's or Titan's representations or
Warranties under the Titan Agreement) or any negligence or misconduct by
Novartis, Titan or HMRI. Vanda shall also indemnify, defend and hold Novartis,
Titan, HMRI and their respective Affiliates harmless from and against any and
all Liabilities incurred by or rendered against Novartis, Titan, HMRI and their
respective Affiliates which arise out of [*] from and after the Effective Date
of this Sublicense Agreement, whether such contracts or arrangements with Third
Parties were entered into prior to or following the Effective Date of this
Sublicense Agreement, except to the extent that such Liabilities are directly
attributable to the breach of this Sublicense Agreement by Novartis or breach of
the Titan Agreement by HMRI or Titan (including without limitation any breach of
Novartis' representations or Warranties under this Sublicense Agreement or any
breach of HMRI's or Titan's representations or warranties under the Titan
Agreement) or any negligence or misconduct by Novartis, Titan or HMRI.

12.6 Novartis shall indemnify, defend and hold Vanda, its Affiliates and
Sublicensees harmless from and against any and all Liabilities (as defined in
Section 12.5 hereof), incurred by or rendered against Vanda, its Affiliates and
Sublicensees, which arise out of [*], except to the extent that such Liabilities
are directly attributable to the breach of this Sublicense Agreement by a third
party (including without limitation any breach of Novartis' representations and
warranties under this Sublicense Agreement), or any negligence or misconduct by
Vanda, HMRI or Titan. Novartis shall also indemnify, defend and hold Vanda, its
Affiliates and Sublicensees harmless from and against any and all Liabilities
incurred by or rendered against Vanda, and its Affiliates and Sublicensees which
arise out of

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 39 of 59
<PAGE>
[*].

12.7 Each party shall give the other prompt notice in writing of any claim or
demand referred to in Sections 12.5 or 12.6. In addition, the obligations of any
indemnifying party shall be subject to the indemnified party fulfilling the
following obligations:
(a) With respect to third party claims, indemnified party
shall fully cooperate with the indemnifying party in the defense of such claim
or demand which defense shall be controlled by the indemnifying party; and
(b) With respect to third party claims, indemnified party shall not, except at
its own cost, voluntarily make any payment or incur any expense with respect to
any claim, demand or suit (including without limitation retaining its own
counsel) without the prior written consent of the indemnifying party, which such
party shall not be required to give.

13. FORCE MAJEURE.

13.1 If the performance of any part of this Sublicense Agreement by either
party, or if any obligation under this Sublicense Agreement, is prevented,
restricted, interfered with or delayed by reason of any cause beyond the
reasonable control of the party required to perform, the party so affected, upon
giving written notice and written evidence of such force majeure to the other
party, shall be excused from such performance to the extent of such prevention,
restriction, interference or delay, provided that the affected party shall use
its reasonable commercial efforts to avoid or remove such causes of
non-performance and shall continue performance with the utmost dispatch whenever
the force majeure is removed. In the event of a force majeure, the parties
shall also discuss whether modification of the terms of this Sublicense
Agreement are necessary to alleviate the hardship or loss caused by the force
majeure.

14. GOVERNING LAW AND ARBITRATION.

14.1 This Sublicense Agreement shall be deemed to have been made in the State of
New York and its form, execution, validity, construction and effect shall be
determined in

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 40 of 59

<PAGE>
accordance with the laws of the State of New York (without regard to New York's
or any other jurisdiction's choice of law principles).

14.2 In the event of any controversy or claim arising out of or relating to any
provision of this Sublicense Agreement, the parties shall try to settle their
differences amicably between themselves. Any unresolved disputes arising between
the parties relating to, arising out of or in any way connected with this
Sublicense Agreement or any term or condition hereof, or the performance by
either party of its obligations hereunder, whether before or after termination
of this Sublicense Agreement, shall be resolved by final and binding
arbitration. Whenever a party shall decide to institute arbitration proceedings,
it shall give written notice to that effect to the other party. Except in the
case of a determination to be made where payments are to be made to by one party
to the other, the party giving such notice shall refrain from instituting the
arbitration proceedings for a period of [*] following such notice to allow the
parties time to further attempt to come to an amicable resolution of the
dispute. Arbitration shall be held in New York City, New York according to the
commercial rules of the American Arbitration Association ("AAA"). The
arbitration will be conducted by a panel of three arbitrators appointed in
accordance with AAA rules; provided, however, that each party shall within [*]
after the institution of the arbitration proceedings appoint a party arbitrator,
and the party-arbitrators shall select a neutral arbitrator, to be chairman of
the arbitration panel, within [*] thereafter. If the party-arbitrators are
unable to select a neutral within such period, the neutral shall be appointed in
accordance with AAA rules. All arbitrator(s) eligible to conduct the arbitration
must agree to render their opinion(s) within [*] of the final arbitration
hearing. No arbitrator (nor the panel of arbitrators) shall have the power to
award punitive damages under this Sublicense Agreement and such award is
expressly prohibited. Decisions of the arbitrator(s) shall be final and binding
an all of the parties. Judgment on the award so rendered may be entered in a
court having jurisdiction thereof. In any arbitration pursuant to this
Sublicense Agreement, the arbitrators shall interpret the express terms hereof
and apply the laws of the State of New York. [*]. Notwithstanding the provisions
of this clause, either party may seek preliminary or injunctive measures or
relief in any competent court having jurisdiction.

15. SEPARABILITY

15.1. In the event any portion of this Sublicense Agreement not material to the
remaining portions shall be held illegal, void or ineffective, the remaining
portions hereof shall remain in full force and effect.

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 41 of 59
<PAGE>
15.2 If any of the terms or provisions of this Sublicense Agreement are in
conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law.

15.3 In the event that the terms and conditions of this Sublicense Agreement are
materially altered as a result of Sections 15.1 or 15.2, the parties shall
renegotiate the terms and conditions of this Sublicense Agreement so as to
accomplish as nearly as possible the original intentions of the parties.

16. ENTIRE AGREEMENT

16.1 This Sublicense Agreement and the Appendices attached hereto, entered into
as of the date written above, constitutes the entire agreement between the
parties relating to the subject matter hereof and supersedes all previous
writings and understandings, including the Confidentiality Agreement between the
parties dated June 16,2003 (it being understood and agreed that all Confidential
Information of HMRI, Titan and Novartis disclosed to Vanda prior to the
Effective Date of this Sublicense Agreement shall be subject to Sections
6.4,6.6, 6.7 and 6.9 of this Sublicense Agreement). No terms or provisions of
this Sublicense Agreement shall be varied or modified by any prior or subsequent
statement, conduct or act of either of the parties, except that the parties may
amend this Sublicense Agreement by written instruments specifically referring to
and executed in the same manner as this Sublicense Agreement. Any amendments to
this agreement require the prior written approval of Titan and HMRI, which
approval will not be unreasonably withheld.

17. NOTICES

17.1 Any notice required or permitted under this Sublicense Agreement shall be
in writing and in English and shall be sent by airmail, postage prepaid, or
facsimile or courier to the following address of each party or to such other
address as may be designated in writing by the respective parties:

If to NOVARTIS:
Novartis Pharma AG
[*]
Basel
Switzerland
Facsimile: [*]

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 42 of 59
<PAGE>
Attention: [*]

With a copy to:
[*]
Novartis Pharma AG
[*]
Basel
Switzerland
Attention: [*]

If to Vanda:
Vanda Pharmaceuticals Inc.
[*]
Princeton, NJ 08542
Attn: [*]

17.2 Any notice required or permitted to be given concerning the Sublicense
Agreement or HMRI Agreement shall be effective upon receipt by the party to whom
it is addressed.

If to TITAN:
Titan Pharmaceuticals, Inc.
[*]
South San Francisco, CA 94080
Attention: [*]
Telephone: [*]
Facsimile: [*]

With a copy to:
Titan Pharmaceuticals, Inc.
[*]
South San Francisco, CA 94080
Attention: [*]
Telephone: [*]
Facsimile: [*]
and
Loeb & Loeb LLP

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 43 of 59
<PAGE>
[*]
New York, New York 10154
Attn: [*]
Phone: [*]
Facsimile: [*]
e-mail: [*]

If to HMRI:
Aventis Inc.
[*]
Bridgewater, NJ 08807-0890
Facsimile: [*]
Attn: [*]

With copies to:
Aventis Inc.
[*]
Bridgewater, NJ 08807-0890
Facsimile: [*]
Attn: [*]

For safety and Adverse Event Reporting:
AVENTIS Inc.
[*]
Bridgewater, NJ 08807-0890
USA
Fax: [*] Phone: [*]
Email: [*]

With copies to:
AVENTIS Inc.
[*]

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 44 or 59
<PAGE>

[*]
Bridgewater, NJ 08807-0890
USA
Phone: [*]
Email: [*]
And,
AVENTIS Inc.
[*]
Bridgewater, NJ 08807-0890
USA
Fax: [*]
Phone: [*]
Email: [*]

18. ASSIGNMENT

18.1 This Sublicense Agreement or any portions thereof and the sublicenses
herein shall be binding upon and inure to the benefit of the successors in
interest and assignees of the respective parties.

18.2 Vanda may assign this Sublicense Agreement to an Affiliate without the
prior written consent of Novartis, and in such event Vanda will continue to
guarantee the obligations of such Affiliate hereunder. Subject to the foregoing,
Vanda shall not have the right to assign this Sublicense Agreement to any Third
Party without the prior written consent of Novartis, Titan and HMRI, such
consent not to be unreasonably withheld; provided, however, that no such consent
shall be required in connection with an assignment in connection with any event
referred to in Section 18.3 below.

18.3 In the event of a consolidation, merger, acquisition which involves a
change in control of Vanda, this Sublicense Agreement shall remain in full force
and effect, and Vanda agrees to notify Novartis, Titan and HMRI. Consolidation,
mergers and/or acquisitions to which

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 45 of 59
<PAGE>
Vanda is a party which do not involve a change in control of Vanda shall not
require such notice.

18.4 In order for any assignment by Vanda of this Sublicense Agreement (which is
permitted by this Sublicense Agreement) to be valid, the assignee of such
assignment shall assume and agree to be bound by the provisions hereof.

19. FAILURE TO ENFORCE

19.1 The failure of either party to enforce at any time any provisions hereof
shall not be construed to be a waiver of such provision nor of the right of such
party thereafter to enforce each and every such provision.

20. AGENCY

20.1 Except as expressly set forth in this Sublicense Agreement, nothing in this
Sublicense Agreement authorizes either party to act as agent for the other or,
as to any third party, to indicate or imply the existence of any such agency
relationship. The relationship between the parties is that of independent
contractors.

21. FURTHER ASSURANCES

21.1 Each party hereto agrees to execute, acknowledge and deliver such further
instruments, and to do all such other acts, as may be necessary or appropriate
in order to carry out the purposes and intent of this Sublicense Agreement.

22. CAPTIONS

22.1 Captions are inserted for convenience only and in no way are to be
construed to define, limit or affect the construction or interpretation hereof.

23. MISCELLANEOUS

23.1 Both parties agree to discuss matters arising during the term of this
Sublicense Agreement in the spirit of co-operation and good faith and endeavour
to resolve any differences by mutual agreement whenever possible. If the parties
fail to reach agreement, either party may submit the matter for resolution
pursuant to Section 14.2.

                                 Page 46 of 59
<PAGE>
23.2 HMRI and its Affiliates shall be third party beneficiaries under this
Sublicense Agreement to the extent that this Sublicense Agreement inures to the
benefit of HMRI, with respect to Sections 2.1(a), 2.4, 2.5, 2.7, 2.9(a), 2.9(d),
2.10, 3.4(a), 3.5, 4.1(a), 4.2, 4.3, 5.2, 5.3, 5.5, 6.3, 6.4, 6.7, 8.1, 8.2,
8.4, 8.5, 8.6, 8.7, 8.9, 8.10, 8.11, 8.12, 8.13, 9.1, 9.3, 9.4, 9.5, l0.1(b),
11.5, 12.5, 17.2, 18.2, 18.3, 18.4,23.2 and 23.3 with all rights and remedies
associated therewith.

23.3 Vanda covenants to Novartis that during the term of this Sublicense
Agreement, Vanda, its Affiliates and Sublicensees shall not violate the Federal
Foreign Corrupt Practices Act in the performance of its negotiations or
obligations hereunder.

   ***[Remainder of page intentionally left blank - signature page follows]***

                                 Page 47 of 59
<PAGE>
IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their duly authorized representatives as of the Effective Date.

                                     VANDA PHARMACEUTICALS, INC.

                                     By: /s/ Mihael Polymeropoulos
                                         ---------------------------------------
                                         Mihael Polymeropoulos
                                         Chief Executive Officer

                                     NOVARTIS PHARMA AG

                                     By: /s/ Herve Girsault
                                         ---------------------------------------
                                         Name:  Herve Girsault
                                         Title: Head, Global Partnering
                                                Business Development & Licensing

                                     By: /s/ Tom Chakraborti
                                         ---------------------------------------
                                         Name:  Tom Chakraborti
                                         Title: Senior Legal Counsel

                                 Page 48 of 59
<PAGE>
                               List of Appendices

Patents and Patent Applications                                       Appendix A

blank                                                                 Appendix B

blank                                                                 Appendix C

blank                                                                 Appendix D

blank                                                                 Appendix E

blank                                                                 Appendix F

Titan Agreement                                                       Appendix G

                                 Page 49 of 59
<PAGE>
                                                                      APPENDIX A

HMRI PATENTS AND PATENT APPLICATIONS

[*]

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 50 of 59
<PAGE>

                                      [*]

                                 Page 51 of 59
<PAGE>

                                      [*]

                                 Page 52 of 59
<PAGE>

                                      [*]

                                 Page 53 of 59
<PAGE>
                                                                      APPENDIX B

BLANK

                                 Page 54 of 59
<PAGE>
                                                                      APPENDIX C

BLANK

                                 Page 55 of 59
<PAGE>
                                                                      APPENDIX D

BLANK

                                 Page 56 of 59
<PAGE>
                                                                      APPENDIX E

CRO CONTRACTS

NONE

                                 Page 57 of 59
<PAGE>
                                                                      APPENDIX F

SPECIAL COUNTRIES

                                 Page 58 of 59
<PAGE>
                                                                      APPENDIX G

TITAN AGREEMENT

[*]

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                 Page 59 of 59
<PAGE>
                        ADDENDUM TO SUBLICENSE AGREEMENT

                                    between

                               NOVARTIS PHARMA AG

                                      and

                          VANDA PHARMACEUTICALS, INC.

This Addendum is part of the SUBLICENSE AGREEMENT that became effective on the
4th day of June, 2004, between Vanda Pharmaceuticals, Inc., a corporation
organized and existing under the laws of the State of Delaware and having its
principal office at 47 Hullfish Street, Suite 310, Princeton, NJ 08542
("Vanda"), and Novartis Pharma AG, a corporation organized under the laws of
Switzerland and having its principal office at Lichstrasse 35, CH-4056, Basel,
Switzerland ("Novartis").

EXCHANGE OF INFORMATION AND CONFIDENTIALITY

The parties agree to be bound to the following terms, and hereby incorporate
them into the Sublicense Agreement.

      1.0 Privacy and Security of Pharmacogenetic samples and data

Vanda agrees that all pharmacogenetic information that it receives in connection
with this agreement, including any DNA samples and/or animal tissues treated
with the compound that may be provided for further studies in accordance with
the Sublicense Agreement terms, as well as any raw data and individual clinical
genetic data and information, will be maintained in a confidential and secure
manner, in full compliance with applicable United States (federal and state),
European Union, and other country specific regulations for privacy and security
of genetic data and samples and personally identifiable health information, and
will only be used and/or disclosed in accordance with those regulations. Vanda
also agrees to ensure that any of its affiliates, agents, vendors or other
business partners who receive any identifiable genetic information or data from
Vanda relating to the compound, shall adhere to the same standards of privacy
and security mandated by this Addendum and the Sublicense Agreement.

                                  Page 1 of 3
<PAGE>
      2.0 Privacy and Security of Adverse Event information.

Vanda agrees that all personally identifiable adverse event information that it
receives in connection with this agreement, including spontaneous adverse event
report forms from Novartis, will be maintained in a confidential and secure
manner, in full compliance with applicable United States (federal and state),
European Union, and country specific regulations for privacy and security of
personally identifiable health information, including any specific requirements
that may apply to adverse event reporting information, and will only be used or
disclosed in accordance with those regulations. Vanda also agrees to ensure that
any of its affiliates, agents, vendors or other business partners (excluding
health authorities) who receive any identifiable adverse event information from
Vanda relating to the compound, shall adhere to the same standards of privacy
and security mandated by this Addendum and the Sublicense Agreement.

      3.0 Compliance with Informed Consents.

Vanda will assume all obligations of Novartis contained in the informed consents
with the individual participants in the studies transferred to Vanda. In case
only the genetic information or study data of such studies is transferred to
Vanda, Vanda will comply with any request by Novartis pursuant to a disclosure,
deletion or destruction request received by Novartis from an individual
participant of such study.

      4.0 Indemnification

Vanda agrees to indemnify and hold harmless Novartis for damages and legal fees
that may result from [*]. Vanda shall also provide written notification to
Novartis of any claim against Vanda relating to [*], within [*] of receipt of
such claim, lawsuit or notification. Vanda agrees that Novartis shall be
permitted to select counsel of its own choosing in the event that a claim or
lawsuit is filed that impacts Novartis' interests.

  *** Remainder of page intentionally left blank, signature page to follow ***

----------
[*] CERTAIN INFORMATION ON THIS PAGE HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE
OMITTED PORTIONS.

                                  Page 2 of 3
<PAGE>
IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their duly authorized representatives as of the Effective Date.

                                       VANDA PHARMACEUTICALS, INC.

                                       By:    /s/ Chip Clark
                                              ----------------------------------
                                       Name:  Chip Clark
                                       Title: Chief Business Officer

                                       NOVARTIS PHARMA AG

                                       By:    /s/ Herve Girsault
                                              ----------------------------------
                                       Name:  Herve Girsault
                                       Title: Head, Global Partnering
                                              Business Development & Licensing

                                       By:    /s/ Kimberly J. Urdahl
                                              ----------------------------------
                                       Name:  Kimberly J. Urdahl
                                       Title: Head of Legal, Primary Care

                                  Page 3 of 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00097-of-00352.parquet"}]]